
BIOINFORMATICS.NET

Community Newsletter

NOVEMBER 2026 · CONNECT · COLLABORATE · ADVANCE

SPONSORED



Illumina sequencing



DNAnexus platform



QIAGEN sample to insight



Cloud genomics workflows

COMMUNITY NEWS

BIOSPACE · NOV 5, 2026

RevMed's Rasonque shatters analyst estimates with $198M quarter

Pent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts' sales expectations and reach 5,000 patients in the third quarter.

Remarkable, historic, impressive, outstanding, stellar—these are a few of the words analysts used to describe the launch of Revolution Medicines' pancreatic cancer medicine Rasonque.

RevMed reported $198 million in revenue for the asset on Wednesday, despite only five weeks of sales following its late August approval. The value was 10 times Truist Securities' $19 million estimate.

"'Que the duck boats," Truist Securities quipped on Wednesday evening.

That revenue stems from the more than 5,000 patients Rasonque has so far reached, RevMed's Chief Global Commercialization Officer Anthony Mancini said on a Wednesday afternoon earnings call. The impressive launch reflects pent-up demand for the RAS inhibitor, analysts said, which arrived on the market to cheers from across the industry and beyond.

Patients with pancreatic cancer had few options prior to Rasonque, with the disease among the deadliest forms of cancer. The drug was cleared in August for treating adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

Rasonque arrived to "a sizable bolus of treatment option-exhausted patients," Leerink Partners wrote on Thursday morning.

RevMed could become ‘next oncology titan’ with Rasonque nod

A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist Securities.

August 27, 2026

Tristan Manalac

Specifically, demand was driven by three channels, Mancini explained. First, RevMed worked to convert participants in the Early Access Program (EAP) into commercial patients, an effort that was completed for U.S. users in the quarter. “We prioritized continuity of care and successfully supported patients in obtaining their medication through the transition,” he said.

Then there were those treatment-exhausted patients, who Mancini said included patients who were later in their treatment journey and had been waiting for a new option.

The third pillar was patients newly diagnosed with second-line disease, where RevMed was particularly impressed with uptake.

“We’re encouraged by the speed with which we were able to begin serving patients following approval, which reflects the significant unmet need in metastatic pancreatic cancer, the strength of Rasonque’s clinical profile and label, the strong launch readiness and initial execution across functions as well as payer engagement and patient support in line with our expectations,” Mancini said.

But the commercial chief also sought to temper expectations about how this launch curve may flatten out. “These early results are highly encouraging. At the same time, with only five weeks of commercialization activity, it’s too early to draw conclusions about the normalized trajectory of the launch,” he said. The EAP patients and those awaiting new options in particular represent a “finite” group of patients.

“As our launch matures, revenue will increasingly reflect ongoing treatment for newly eligible patients and ongoing treatment duration,” Mancini said.

Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings

Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.

October 13, 2026

Annalee Armstrong

Still, analysts were bullish on Rasonque’s growth potential. For the rest of the year, RevMed will look to bring on new patients as they advance to second line treatment for the disease. Leerink revised sales expectations to $440 million for the fourth quarter, compared to $330 million on the high end of previous estimates.

RevMed is still working on insurance coverage for Rasonque as well, Mancini noted.

Meanwhile, RevMed CEO Mark Goldsmith wants to make the drug available all over the world so that all patients with the difficult cancer may benefit. Europe’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion of the drug, with a formal approval decision pending with the European Medicines Agency.

Digging in

RevMed reported a net loss of $407.5 million for the third quarter, compared to $305.2 million for the same period a year earlier. The company had $3.7 billion in cash on hand as of September 30, not including royalty payments that began flowing from Royalty Pharma in line with Rasonque sales. The company expects to invest deeper into its RAS(ON) inhibitor portfolio while supporting launch efforts for Rasonque into 2027, according to CFO Jack Anders.

Meanwhile, the biotech will also move toward adding additional lines of treatment for Rasonque, including first-line metastatic and resectable disease. Enrollment for the Phase 3 RASolute 303 trial studying the drug alone and with chemotherapy in patients with first-line metastatic pancreatic cancer recently wrapped in the U.S., Chief Development Officer Alan Sadler said on the call. And dosing has begun in another first-line Phase 3 test called RASolute 309, which features patients with RAS G12D pancreatic cancer. This study pairs Rasonque with RevMed's up-and-coming therapy zoldonrasib.

RevMed is also running two other Phase 3 trials of Rasonque, RASolute 304 in the adjuvant setting and RASolute 305 in first-line, as well as studying the drug in non-small cell lung cancer, where RAS mutations drive disease. Zoldonrasib, meanwhile, is also under investigation in colorectal cancer.

RevMed has key clinical development partnerships with BeOne Medicines and Summit Therapeutics underway as well, featuring Rasonque and other pipeline assets.

"Rasonque's approval and launch mark a monumental step forward for patients living with RAS-dependent cancers and open an important new chapter for Revolution Medicines," Goldsmith said. "With this momentum, we continue our deep commitment to discovering, developing and delivering innovative targeted medicines with the urgency patients deserve."

Drugmakers rush to pair up with Summit's ivonescimab ahead of key verdict

With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics' Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset "the next major backbone" of cancer treatment.

November 2, 2026

Tristan Manalac

BIOSPACE · NOV 5, 2026

T-time: British biotech pours $133M into the pot for bispecifics

With backing from three Big Pharma investment arms, British biotech T-Therapeutics is brewing up a clinical launch for its cancer and autoimmune T cell engagers.

T-Therapeutics has bagged $133 million in series B funding to move its next-gen T cell engager therapeutics into the clinic for cancer and autoimmune diseases.

The oversubscribed series B was co-led by new investors Advent Life Sciences and British Business Bank, with participation from a slew of Big Pharma backers, including Johnson & Johnson Innovation, Eli Lilly and Sanofi Ventures, among other investors.

The U.K. biotech will use the new cash infusion to speed its T cell receptor (TCR) bispecific lead programs into the clinic. The cancer asset, dubbed TTX-008, targets CD3 for solid tumors, while the immunology candidate, called TTX-018, targets the same protein complex but for autoimmune and inflammation disorders.

Both programs stem from T-Therapeutics' OpTiMus platform, which provides fully human TCRs to tackle historically difficult-to-reach intracellular targets. Initially formed in 2022, the biotech raised a total of $91 million in series A money after closing an extension in November 2025.

"This financing is a key step in our transition to a clinical-stage company, enabling us to accelerate the development of two oncology and immunology programs with pan-indication, blockbuster potential, underpinned by a platform that reaches targets long considered undruggable," T-Therapeutics CEO Theodora Harold said in a Thursday release.

At the same time, the U.K. startup is also welcoming Kirsty Crame aboard as chief development officer. Crame previously served as Swiss pharma Curatis' chief medical officer, with experience at Medigene and Gadeta before that.

US biotechs take lion's share of $54.5B VC money raised since 2025

Since 2025, U.S. biopharma companies have raised $37.2 billion—68% of total worldwide venture capital funding in the industry—with startups in the San Francisco Bay Area and Boston leading the way.

October 26, 2026

Gabrielle Masson

On the same day, another British biotech secured venture capital to transition into a clinical-stage company. Oxford-based Alethio Therapeutics announced an oversubscribed $90 million series A that will go toward its myeloproliferative neoplasm (MPN) candidate for a rare, chronic blood cancer. The round was co-led by biotech venture capital firms Sofinnova Partners and RA Capital.

Over the past two years, U.S. biotechs have raised the majority of private venture capital financing with $37.2 billion, or 68% of the worldwide total, according to an October report from J.P. Morgan.

Outside of the U.S., European biopharma companies raised $9.2 billion from 2025 through 2026's third quarter, accounting for just under 17% of all capital deployed. The U.K. raised the largest share, securing $3.1 billion across 58 rounds.

BIOSPACE · NOV 5, 2026

Novartis subsidiary Avidity will lay off 40 in San Diego

Follow along as BioSpace tracks job cuts and restructuring initiatives.

Below is a look at which companies are tightening their belts and cutting staff in 2026. For last year's tracker

entries, please visit the 2025 recap article. To see which biopharmas laid off employees in the years prior to 2025, check out our 2023 and 2024 recaps.

Know about a layoff happening in biopharma? Feel free to contact Angela Gabriel at angela.gabriel@biospace.com.

Avidity Biosciences

Avidity Biosciences, a wholly owned subsidiary of Novartis, is letting go of 40 employees, with the cuts happening on a rolling basis beginning Dec. 31.

The layoffs will mostly affect on-site workers at the San Diego–based biotech, although seven remote employees will also be impacted, according to the full Worker Adjustment and Retraining Notification (WARN) Act notice obtained by BioSpace. Areas of the company being cut include clinical operations, clinical research, medical writing, regulatory affairs and regulatory operations.

Avidity had 511 employees as of Feb. 13, so the layoffs will likely affect a small proportion of the company's workforce. The cuts were disclosed in a WARN notice in late October, about eight months after Novartis completed its acquisition of the biotech, which develops rNA therapeutics.

Novartis To 'Bolster' Neuromuscular Pipeline With $12B Avidity Acquisition

The deal, announced early Sunday afternoon, will see Novartis gain access to Avidity's neuroscience assets, while the San Diego biotech spins out a new company to shepherd its early-stage precision cardiology programs.

October 26, 2025

Heather McKenzie

Akebia Therapeutics

Akebia Therapeutics laid off 7% of its staff in July, according to a Nov. 5 SEC filing. The biotech had 194 employees as of Dec. 31, 2025, meaning the layoffs would have left Akebia with around 181 people.

The layoffs are associated with a restructuring intended "to improve our operational efficiency to align with our current priorities," according to the regulatory filing. Expenses related to the restructuring totaled $1.3 million in the third quarter.

The news came as the Cambridge, Massachusetts–based company reported third quarter earnings on Thursday, clocking a $14.4 million loss—a hit after reporting profitability in Q3 2025.

As of the end of September, Akebia had cash and cash equivalents of $159.3 million and restricted cash of $0.9 million.

UltragenyxNov. 4

Ultragenyx is undertaking "substantial headcount and expense reductions" according to its third quarter earnings report on Tuesday. The job cuts—which will claim around 20% of the rare disease outfit's workforce—come as Ultragenyx is "entering a new stage focused on commercial execution and a smaller, more targeted R&D footprint."

The workforce reduction will leave Ultragenyx with approximately 1,000 employees, according to the release.

The strategy shift follows an up and down year in which Ultragenyx won approval for its first two gene therapies—for glycogen storage disease in August and Sanfilippo syndrome type A in September. Also in September, however, the company's investigational Angelman syndrome therapy apazunersen failed to improve cognition in a Phase 3 clinical trial, missing the trial's key endpoints and sending Ultragenyx's stock crashing more than 43%.

With the headcount and expense reductions, Ultragenyx expects to reduce R&D expenses to less than $350 million in 2027 and selling, general and administrative expenses to less than $375 million. Additional savings actions include completing the wind-down of all ongoing studies of GTX-102 for Angelman syndrome, axing a Wilson disease candidate, UX701, after it did not achieve its study goals and a reduction of the biotech's real estate footprint.

In addition to these expense reductions, Ultragenyx will be primarily focused on "driving successful launches" for Genglycos in glycogen storage disease and Fayuvi in Sanfilippo syndrome.

Vistagen TherapeuticsNov. 2

Seven months after laying off about 20% of its employees, Vistagen Therapeutics let go of around 31% of its remaining staff. The move, completed Oct. 26, is meant to reduce operating expenses, preserve capital and align workforce size and structure with late-stage clinical priorities, according to an SEC filing.

The South San Francisco, California–based company had 41 full-time employees as of June 30, meaning the latest cuts may have affected around 13 people. Vistagen kept core clinical, regulatory, technical and corporate capabilities needed for U.S. registration–directed Phase 3 development of fasedienol, its lead product candidate for the treatment of social anxiety disorder. In August, the company announced that asset had not significantly outperformed placebo in a small Phase 2 study.

The remaining employees could also work on potential future development of Phase 2 product candidates itruvone for major depressive disorder and refisolone for menopausal hot flashes.

Vistagen estimates it will incur about $1 million in severance and termination costs and that the layoffs will save around $3.2 million annually in salary and benefits. The company had cash, cash equivalents, and marketable securities of $31.7 million as of June 30, down from $45.4 million on March 31.

Neuropsychiatric disorders

Vistagen's repeat-dose anxiety nasal spray can't beat placebo in mid-stage study

The Phase 2 study was small and was not designed to establish the statistical difference between Vistagen's drug candidate and placebo, according to Vistagen. The biotech plans to meet with the FDA to determine a registrational path for the asset.

August 7, 2026

Tristan Manalac

ImmutepOct. 30

Following a Phase 3 study futility outcome, Immutep has initiated cost-reduction measures that include layoffs to preserve capital and extend its cash runway. The Australia-based biotech did not specify the number of employees or locations affected in its Oct. 29 announcement but said most cuts happened at the start of fiscal year 2027, which began July 1. BioSpace has contacted the company for details.

Immutep, which is developing novel immunotherapies for the treatment of cancer and autoimmune diseases, had 46 employees as of June 30, prior to the cuts. That figure was down from 51 on June 30, 2025.

In March, Immutep announced it was discontinuing its TACTI-004 Phase 3 study. The study was evaluating novel immunotherapy eftilagimod alfa in combination with Merck's Keytruda and chemotherapy as a first-line therapy for patients with advanced or metastatic non-small cell lung cancer, regardless of PD-L1 expression. An Australian independent data monitoring committee recommended the discontinuation after an analysis found the trial unlikely to meet its goal.

Immutep has cash and term deposits of about $34.1 million as of Sept. 30. The biotech expects its cash runway to extend "well into" the first half of 2028.

Molecular PartnersOct. 30

As it focuses resources on developing its radiopharmaceuticals pipeline, Molecular Partners plans to lay off up to 44% of its workforce, which could be as many as 55 employees. The Switzerland-based biotech expects to complete the cuts by the second quarter of 2027, the company announced Oct. 29.

Molecular did not specify if the workforce reduction will affect its Cambridge, Massachusetts, location.

The company noted in its announcement that it was encouraged by emerging Phase 1/2a data from MP0712, a targeted alpha radiotherapy for the treatment of small cell lung cancer. Molecular expects efficacy data for MP0712, which it's co-developing with Orano Med, in 2027. The biotech is also working to advance its pipeline of Radio-DARPin (designed ankyrin repeat protein) therapeutics. The custom-built medicines are based on natural binding proteins for the treatment of medical conditions that other modalities can't readily address, according to Molecular.

The biotech expects that its cash and cash equivalents of CHF 57.5 million, or $69 million, as of Sept. 30 will fund the company into late 2027.

LENZ TherapeuticsOct. 29

As part of a strategic reorganization announced Wednesday and intended in part to "streamline the organization," LENZ Therapeutics will decrease headcount by about 75% to around 40 full-time employees, according to an SEC filing from the same day. The strategy shift, which the biotech disclosed alongside third quarter earnings that fell short of expectations, is meant to "prioritize consumer marketing, allocate capital to maximize sales growth, and reduce operating expenses."

Among the employees departing the company are president and CEO Eef Schimmelpennink. CFO Dan Chevallard will take the reins as interim president and CEO.

LENZ estimates the reorganization will cost approximately $5 million in severance payments, related termination benefits and other nonrecurring charges. These charges are anticipated by the end of the year, during which time the reorganization "will be substantially completed."

LENZ's stock has fallen nearly 80% since the start of the year.

GSK's three-year restructuring plan is hitting its home country, though CEO Luke Miels said the expected U.K. cuts will have a "limited impact."

The undisclosed number of cuts will mainly include “support functions in headquarters,” Miels said on a Wednesday call with reporters. “You never want headquarters to be too big. I want people at the bench in the lab or out there talking to physicians or on the line in a manufacturing environment. That is our priority there.”

The exec didn’t provide more color when asked further about the U.K. changes. A company spokesperson also declined to share specifics with BioSpace.

The news follows layoffs across GSK’s Belgium sites and the pharma’s shuttering of its German vaccine manufacturing site, which prompted job cuts for about 650 employees. The changes are all part of a cost-cutting plan announced this July designed to save $2.5 billion.

Artiva BiotherapeuticsOct. 28

Following two patient deaths and questions about the clinical response durability of its lead candidate, Artiva Biotherapeutics is ending development of the asset, wiping out 94% of its workforce and exploring strategic options. Those options could include a merger, business combination, sale or licensing of assets, or dissolution and liquidation, the San Diego–based biotech announced Oct. 27.

Artiva is letting go of 131 employees effective Dec. 31, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. The move will leave the business with fewer than 10 people.

The biotech’s actions, which include canning a planned Phase 3 pivotal trial, follow a risk-benefit review of AlloNK. Artiva was evaluating the allogeneic, off-the-shelf natural killer cell therapy in combination with rituximab in rheumatoid arthritis and other B-cell-driven conditions.

Editor’s note: BioSpace updated this entry Oct. 30 to clarify how many employees are being let go and the layoffs’ effective date, based on a WARN notice that posted after this entry’s original publication.

After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce

Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other autoimmune diseases, is exploring strategic options that could include dissolution and liquidation.

October 27, 2026

Angela Gabriel

Teva PharmaceuticalsOct. 27

Teva Pharmaceuticals is closing its manufacturing facility in Fairfield, New Jersey, and laying off 61 employees. The cuts will be effective Feb. 1, 2027, according to a Worker Adjustment and Retraining Notification (WARN) Act notice.

In the full WARN notice, Teva briefly explained the reason behind the termination of operations, noting that “Despite efforts to increase production, the site remains underutilized and costly to operate, while declining demand and significant price erosion have further impacted its economic viability.”

The Fairfield cuts are the first known U.S. layoffs for Israel-based Teva in 2026 but not the first overall workforce reduction noted this year. In June, various media outlets reported that over the next two years, the company is letting go of 250 employees from its active pharmaceuticals ingredient (API) division in Israel.

In May 2025, company executives announced Teva will cut 2,900 employees worldwide by 2027.

Tango TherapeuticsOct. 23

As part of a strategic reprioritization of its research and development (R&D) activities, Tango Therapeutics plans to let go of about 14% of its workforce, with most of the cuts affecting its research group. The Boston-based biotech had 137 full-time employees, including 97 in R&D, as of Dec. 31, 2025, meaning the layoffs could affect around 19 people.

Tango will now focus its efforts on advancement of PRMT5-targeted therapies and clinical product candidates vopimetostat and TNG456, according to an Oct. 23 SEC filing. The company will also deprioritize novel target discovery and expects to stop certain preclinical and research activities.

In related news on Oct. 23, Tango announced updated results from its ongoing Phase 1/2 study of pancreatic cancer candidate vopimetostat combined with Revolution Medicines' daraxonrasib, recently greenlit by the FDA as Rasonque for second-line pancreatic cancer. The reported 82% response rate was down from 92% noted in June for fewer patients. During a conference call, Tango CEO Malte Peters said the company expects to seek FDA guidance on a possible accelerated approval path for the combination treatment.

Pancreatic cancer

ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3

A combination of Tango Therapeutics' vopimetostat and Revolution Medicines' recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in June in fewer patients.

October 23, 2026

Heather McKenzie

Ferring PharmaceuticalsOct. 22

A year after announcing it would lay off up to 500 employees, Ferring Pharmaceuticals is again trimming its workforce. The Switzerland-based pharma has focused its U.S. resources on areas that better support its strategic priorities and allow it to continue delivering for patients and customers, according to a company statement provided to BioSpace Thursday.

"As a result, a limited number of employees will leave the company," the statement continued. "All affected individuals will have the opportunity to apply for other positions within Ferring, and we are supporting those who are leaving through this transition."

Ferring did not provide details on the number of people or locations affected nor the exact timing of the cuts. However, in a LinkedIn post Wednesday, a now-former employee said they had been impacted by organizational layoffs, indicating the workforce reduction has already begun.

In early October 2025, Ferring announced it was letting go of up to 500 people so it could sharpen its strategic focus and gain flexibility as a company. A few weeks after that, the company disclosed it was laying off 64 employees in Parsippany, New Jersey, effective this year from Jan. 23 to July 31.

PfizerOct. 22

Pfizer is reportedly cutting hundreds of employees across its operations, based on recent media reports noted by Fierce Pharma. Whether those layoffs are all connected to the $2.5 billion the New York pharma in August added to its ongoing restructuring is unknown.

In early October, Reuters reported that according to trade unions, Pfizer will cut about 330 jobs in Sicily, although a Pfizer statement noted the company supports ongoing discussions and would evaluate “concrete and sustainable alternative proposals.” Additional talks between the pharma, unions and Italy’s industry ministry are scheduled for Nov. 10.

In mid-October, MLive reported that Pfizer had confirmed it would let go of about 150 employees from a facility in Portage, Michigan. The pharma’s statement to MLive connected the cuts to lower volumes at the facility due to lower projected demand for some products manufactured there.

This week, the Triangle Business Journal reported Pfizer is laying off an undisclosed number of employees at its Rocky Mount and Sanford, North Carolina, manufacturing facilities. The timing of that report matches when the company confirmed manufacturing layoffs to BioSpace, although Pfizer did not provide details on how many employees or locations were affected nor the timing of the cuts.

PfizerOct. 21

Pfizer is saying goodbye to an unspecified number of employees across its manufacturing operations, a spokesperson confirmed to BioSpace via email on Tuesday. The company representative declined to disclose how many employees and which sites were affected. Pfizer also didn’t say when these layoffs will take effect.

“Pfizer regularly evaluates our manufacturing network to ensure capacity is effectively utilized based on patient needs, projected product demand, and long-term business objectives,” the spokesperson said. “We’ve conducted a series of these evaluations focused on operational efficiencies, and headcount reductions are a part of this initiative.”

Pfizer is in the midst of a restructuring program, and added $2.5 billion to its savings target in August. Many of these cuts are expected to stem from “technology and simplification efforts” across the company’s manufacturing, R&D and commercial operations—though a spokesperson at the time declined to confirm whether any jobs would be affected.

EnlivexOct. 20

Enlivex is slashing its workforce by around 60% as part of a restructuring initiative to cut costs and channel its resources behind the mid-stage development of Allocetra, an off-the-shelf cell therapy for knee osteoarthritis, the company announced Monday. As of Dec. 31, 2025, Enlivex had 34 full-time employees, as per the company’s annual report, suggesting that the layoffs will affect some 20 people.

The cost-cutting plan will take effect “immediately,” though the company didn’t specify when the layoffs will take place.

Alongside the layoffs, Enlivex will also lower the compensation packages of its senior leaders. CEO Oren Hershkovitz will take a 40% pay cut while the management team will see a 20% reduction in compensation.

In a Phase 1/2a study, Allocetra elicited significant improvements in knee pain and function over placebo at 3 and 6 months, the biotech said Monday. Enlivex now plans to run a placebo-controlled Phase 2b study for the investigational cell therapy, focusing on patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis. The FDA has granted Allocentra Regenerative Medicine Advanced Therapy (RMAT) designation for this indication.

EyePointOct. 20

Following another disappointing readout for investigational tyrosine kinase inhibitor duravyu in wet age-related macular degeneration, EyePoint will undergo a strategic reprioritization that includes cutting about 53% of its workforce. Across its Watertown headquarters and Northbridge manufacturing facility, the layoffs will affect 105 employees from Dec. 31, 2026, to Jan. 31, 2027, according to a Worker Adjustment and Retraining Notification (WARN) Act notice.

On Oct. 19, EyePoint reported that in the topline readout from the Phase 3 Lucia trial, duravyu again failed to match Regeneron Pharmaceuticals' approved wet AMD treatment Eylea. The Watertown, Massachusetts–based biotech is now ending the asset's pivotal wet AMD trials early, the company said in a separate announcement, and will focus resources on its late-stage program for duravyu in diabetic macular edema (DME).

Editor's note: BioSpace updated this entry Oct. 26 to clarify how many employees are being let go based on a WARN notice that posted after this entry's original publication.

EyePoint will halve workforce, end pivotal wet AMD trials early following second fail

EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to the asset's potential in diabetic macular edema.

October 19, 2026

Angela Gabriel

Less than a month after announcing that it would shutter its German manufacturing facility and slash about 650 jobs there, GSK is cutting more than 1,200 roles in Belgium as part of its $2.5 billion global restructuring.

The new layoffs, which could affect as many as 1,217 GSK employees, are part of the organization's three-year plan to reallocate capital and resources toward the pharma's late-stage pipeline and R&D efforts, a spokesperson confirmed with BioSpace on Oct. 14.

The cuts will be spread across GSK's Rixensart, Wavre and Gembloux sites, Belgium news publication L'Echo reported.

GSK plans 1.2K+ layoffs at Belgium sites as $2.5B restructure gains momentum

The layoffs across GSK's Belgium sites come on the heels of the pharma's planned shuttering of its German vaccine manufacturing site, which prompted job cuts for about 650 employees.

October 14, 2026

Gabrielle Masson

Caribou BiosciencesOct. 9

Nearly all Caribou Biosciences employees may soon be jobless as part of the Berkeley, California–based company's workforce cuts. The biotech will let go of 87 employees effective Dec. 7, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. Caribou had 97 employees as of Feb. 27, meaning the layoffs could affect 90% of its staff.

The company announced on Oct. 6 that amidst a financing freeze in the CAR T space, it planned to discontinue further development of its clinical-stage pipeline, implement a “substantial” workforce reduction and explore strategic alternatives. Those alternatives include, but are not limited to, a merger, acquisition, business combination or other strategic transaction involving the biotech and its assets.

Caribou’s last known layoffs were in 2025. In April of that year, the company disclosed in an SEC filing that it was letting go of 47 employees, or about 32% of its staff, and ending work on its lupus pipeline. The pipeline shift left the business with two allogeneic, or “off-the-shelf,” CAR T products for various types of cancer.

Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up

Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including Novartis, AbbVie and Pfizer.

October 7, 2026

Tristan Manalac

Caribou BiosciencesOct. 8

Caribou Biosciences, co-founded by Nobel Prize-winning CRISPR pioneer Jennifer Doudna, is discontinuing its entire clinical-stage pipeline and executing “substantial” workforce cuts amid a financing freeze in the CAR T space.

As part of a strategic review, Caribou could consider a merger, acquisition, business combination or other strategic transactions involving the company and/or its assets. The decision, disclosed in an Oct. 6 news release, “reflects the difficult reality that the current financing environment for allogeneic CAR-T cell therapies has made it impossible to secure the capital required to responsibly advance them,” CEO Rachel Haurwitz wrote in a LinkedIn post.

Related to Caribou’s efforts to seek out strategic alternatives, the company will enact a “substantial reduction” of its headcount, though the number of people affected was not revealed. Caribou had 97 full-time employees as of Feb. 27, 2026, according to an annual SEC report. The company expects to absorb around $15 million to $19 million in restructuring costs.

Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up

Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including Novartis, AbbVie and Pfizer.

October 7, 2026

Tristan Manalac

Adecto Pharmaceuticals and Aviceda TherapeuticsOct. 6

Adecto Pharmaceuticals and Aviceda Therapeutics are exiting the biotech scene, although Adecto’s CEO hopes the company’s work can continue.

Adecto CEO Nora Minerva announced on LinkedIn last week that the business, which had been developing a treatment for cancers that aren’t responsive to conventional immunotherapy, had officially closed its doors. The Boston-based biotech’s website indicates operations ceased Sept. 30.

Aviceda, which had planned to take an eye drug into a Phase 3 clinical trial, is also winding down, according to a source familiar with the decision, Endpoints News reported Oct. 2. The publication also cited an employee's LinkedIn post that said the business is closing "due to clinical trial results." The biotech was developing therapies to treat retinal diseases. An Aviceda asset missed its primary endpoint in a Phase 2b clinical trial, the biotech announced in December.

BioSpace has contacted Adecto and Aviceda for comment and to confirm the number of employees the closures will affect. According to their LinkedIn profiles, Adecto had between two and 10 employees, while Aviceda has 51 to 200.

2 Massachusetts biotechs call it quits

Adecto Pharmaceuticals has ceased operations, while Aviceda Therapeutics is in the process of winding down.

October 5, 2026

Angela Gabriel

Foghorn TherapeuticsOct. 2

Foghorn Therapeutics and Eli Lilly have ended their collaboration on oncology products, resulting in the Watertown, Massachusetts–based biotech reprioritizing its pipeline and cutting about 40% of its workforce.

Foghorn, which is developing product candidates in oncology and in immunology and inflammation, expects to mostly complete the layoffs this quarter, according to an SEC filing. The move will leave the business with about 65 full-time employees.

Following a recent review of clinical data from the Phase 1 dose escalation trial of cancer candidate FHD-909 (LY4050784), Foghorn and Lilly opted to stop advancement of the small molecule into the clinical development expansion phase, according to the Oct. 1 announcement. The companies are also not advancing a selective SMARCA2 degrader program and don't anticipate further collaboration activities.

Foghorn lays off 40% of staff after Lilly collaboration ends

Foghorn Therapeutics and Eli Lilly teamed up in 2021 to develop and commercialize oncology products. The biotech's layoffs will leave the company with 65 employees as it refocuses on its proprietary portfolio programs.

October 1, 2026

Angela Gabriel

NovoSept. 30

Novo continues to trim its workforce, this time letting go of 108 employees at its Plainsboro, New Jersey, site. These layoffs will take effect Dec. 31, according to a Worker Adjustment and Retraining Notification (WARN) Act notice for the state.

This latest round of cuts comes after CEO Mike Maziar Doustdar earlier this month disclosed that Novo's overall headcount has dropped by around 13,000 people over the past year amid an effort to channel more money into R&D. This total includes the 9,000 terminations announced in September 2025 as part of a savings push.

The remaining 4,000 were disclosed by Doustdar during the company's Capital Markets day earlier this month and also covers retirements, voluntarily exits and attrition, a spokesperson told BioSpace at the time. As of Sept. 23, the pharma had around 67,000 employees worldwide, the spokesperson added.

BioMarin PharmaceuticalsSept. 30

BioMarin is handing 117 employees the pink slip at its Novato, California, location, effective Dec. 4, as per a Worker Adjustment and Retraining Notification (WARN) Act alert. The company's workforce stood at 3,221 employees as of Dec. 31, 2025, according to its annual report.

In May—just weeks after being bought out by BioMarin for $4.8 billion—Amicus Therapeutics cut 58 staff from its headquarters in Princeton, New Jersey, effective from Aug. 7 through Oct. 30. A spokesperson confirmed to BioSpace that the headcount reduction was related to the acquisition.

BioMarin reported a 20% year-on-year increase in second quarter revenues to $990 million.

Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma

Takeda's cuts will go the deepest, affecting over 4,700 employees. Layoffs tied to M&A activity include BioNTech letting go of around 800 people at CureVac.

July 16, 2026

Angela Gabriel

Enanta PharmaceuticalsSept. 30

As part of a "careful evaluation" of its resources and needs, Enanta Pharmaceuticals will part ways with 37 employees, a spokesperson for the company confirmed to Fierce Biotech on Sept. 29. The infectious disease and immunology specialist is based in Watertown, Massachusetts.

As of Sept 30, 2025, Enanta employed 120 full-time employees, according to the company's annual report. During the biotech's fiscal third quarter, which ends on June 30, Enanta brought in $14.4 million in revenues, mostly from royalties from AbbVie's hepatitis C virus medicine Mavyret. Enanta had $211.5 million in cash and marketable securities, enough to continue operations into fiscal year 2029, which starts Oct. 1.

Enanta is advancing a respiratory syncytial virus drug called zelicapavir into a registrational Phase 2b/3 study, focusing on adults who are at high risk of severe outcomes, according to a June announcement. Topline data from the Phase 2b portion are expected next year. The biotech is also planning to study zelicapavir for pediatric patients in 2027.

NovoSept. 23

Novo's workforce has shrunk by about 13,000 individuals over the past year as the Danish weight loss juggernaut works to unify and drive more funds into research and development, CEO Mike Maziar Doustdar said Sept. 21. The company's total workforce now stands at 67,000, a spokesperson confirmed to BioSpace in an emailed response.

The number of employees who have departed includes a previously disclosed 9,000 people laid off as part of a restructuring announced in September 2025, meant to generate $1.25 billion in annualized savings through 2026. Doustdar disclosed 4,000 more exits during Novo's Capital Markets Day on Sept. 21.

The company spokesperson told BioSpace the newly revealed 4,000 departures should not be interpreted as 4,000 additional layoffs. Workforce levels, they said, changed for reasons including normal attrition, retirements, voluntary departures, decisions to not backfill roles and other hiring decisions, as well as organizational changes. They did not specify how many among the 4,000 had been laid off.

Novo's workforce reduction climbs to 13,000 to fuel R&D work

September 22, 2026

Annalee Armstrong

Bristol Myers SquibbSept. 22

The cuts continue at Bristol Myers Squibb, which has lined up 265 employees to be terminated at the pharma's Princeton site in New Jersey. The layoffs will run from Dec. 17 to May 21, 2027, according to a Worker Adjustment and Retraining Notification (WARN) Act alert.

BMS is in the middle of a cost-cutting push, first announced in 2024. The pharma in February 2025 upped its savings goal by $2 billion through 2027. This effort has hit New Jersey hard. In April, for instance, BMS announced it would let go of more than 200 employees at its Lawrenceville location after the site's workforce was reduced by more than 1,000 employees last year.

Johnson & JohnsonSept. 21

Johnson & Johnson is continuing to whittle away its New Jersey workforce. The company is laying off 87 employees in New Brunswick, where it is headquartered, effective Dec. 18, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. In May, J&J disclosed via a WARN alert that it was cutting 56 employees in New Jersey, mainly in New Brunswick but also in Raritan, Somerville and Titusville. The pharma completed that workforce reduction Aug. 21.

Asked about both rounds of layoffs, which affect 143 people total, a company spokesperson told BioSpace in an emailed statement that "As part of our ongoing efforts to operate efficiently and support long-term growth, we continuously evaluate our cost structure and organizational design. As we progress our Orthopedics separation, we are focused on addressing stranded costs and identifying opportunities to further improve operating margins—helping enable continued investment in innovation for patients."

J&J in October 2025 announced it would spin out its orthopedics unit, which is part of its medtech business. The company expected the process would take around 18 to 24 months and would establish DePuy Synthes as a standalone company in 2027. The orthopedics unit generated about $9.2 billion in sales in 2024.

The latest J&J layoffs include employees in tech-focused, engineering and compliance roles and one person at the vice president level, a vice president of procurement CPO med tech.

GSK is consolidating its vaccine manufacturing operations to one site, closing a facility in Germany—a move that will leave about 650 employees without a job.

"Following the review, we have taken a difficult decision to propose consolidating operations at one site," a spokesperson confirmed with BioSpace, referring to the pharma's recently announced $2.5 billion cost-cutting campaign.

The pharma will retain its Canada plant while letting go of its Dresden campus, the spokesperson said. GSK expects that it "can fully match anticipated future demand in a sustainable and competitive way," the spokesperson added.

In July, the U.K. drugmaker announced a sweeping cost-cutting initiative designed to save $2.5 billion over the next three years, an initiative that CEO Luke Miels said will "simplify the organization" and help "reallocate capital and resources" to its late-stage pipeline.

GSK lays off 650 staffers amid closure of German vaccine manufacturing site

GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid the pharma's recent $2.5 billion savings campaign.

September 15, 2026

Tristan Manalac

Sionna TherapeuticsSept. 15

Sionna Therapeutics is restructuring, letting go of 46% of employees as part of an effort to advance a cystic fibrosis combination program and stretch its cash runway.

As part of the reorganization, the Massachusetts-based biotech has terminated the employment of its Chief Business Officer Caroline Stark Beer, effective Tuesday, according to an SEC filing. Furthermore, other execs are taking on extra responsibilities, such as Chief Medical Officer Charlotte McKee assuming the additional role of R&D head, with no changes to compensation.

Sionna is implementing these cost-saving measures to focus resources on moving dual combination SION-451 and SION-2222 into a Phase 2a proof-of-concept trial. The decision follows the failure of a Phase 2a trial for SION-719 as an add-on to standard of care for cystic fibrosis. Sionna's dual combination program is now the only active program in development at the company, according to its online pipeline.

The biotech will be retaining staffers involved with the dual combination program, according to the SEC filing.

As of June 30, Sionna had an accumulated deficit of $313 million, citing significant R&D and manufacturing costs, according to a separate SEC filing. At the end of June, the biotech had $268.3 million on hand, money the company expects to last into 2028.

MerckSept. 9

Merck is terminating 54 jobs at its site in Rahway, New Jersey, according to a Worker Adjustment and Retraining Notification Act alert for the state. These latest layoffs will take effect on Dec. 11 this year and Jan. 4 of next year.

The company's Rahway location has been on the receiving end of numerous workforce reductions over the last year. In June, for instance, Merck announced it was parting ways with 88 employees at the site—a reduction that took effect last week. Merck in August 2025 also said it was laying off 58 Rahway staff, effective Nov. 14 that year.

Merck is in the midst of a $3 billion cost-cutting campaign that could claim 6,000 jobs across its global operations. The effort, which runs through 2027, will help the pharma reallocate some of its funds from slower growth areas to more than 20 upcoming potential launches.

TScan TherapeuticsSept. 4

As part of a strategic reorganization that includes pausing its heme malignancies program and prioritizing its in vivo solid tumor program, TScan Therapeutics is slashing 75% of its workforce, the company announced Sept. 2. The Waltham, Massachusetts–based biotech is letting go of 96 people effective Nov. 2, according to a Worker Adjustment and Retraining Notification (WARN) Act notice.

This is the second set of known layoffs at TScan in less than a year. In November 2025, the company announced it was letting go of 30% of its staff, or 66 employees, as it refocused its pipeline to extend its cash runway into the second half of 2027. The latest workforce cut includes letting go of Jason Amello, chief financial officer, and Chrystal Louis, chief medical officer, effective Sept. 2, according to an SEC filing.

In connection with its strategic reorganization, TScan, which develops T cell receptor–engineered T cell (TCR-T) therapies for the treatment of cancer, is pursuing strategic partnerships for its heme and autoimmune programs. It is also eliminating its internal manufacturing organization and significantly reducing its research footprint.

Editor's note: BioSpace updated this entry Sept. 7 to clarify how many employees were let go based on a WARN notice that posted after this entry's original publication.

TScan cuts 75% of workforce while shifting focus to solid tumor program

TScan Therapeutics is looking for strategic partnerships for its heme and autoimmune programs while working to advance two in vivo T cell therapy candidates into investigational new drug–enabling studies.

September 3, 2026

Angela Gabriel

NovartisSept. 3

Novartis could let go of about 130 employees in Switzerland due to discontinuing small-volume production of biologics in Kleinbasel by the end of 2027, the company announced in a German-language press release. Fierce Biotech first reported the news.

The discontinuation is tied to Novartis relocating laboratories for supporting biological cell banks, analytical testing and technical development activities to Basel by the end of 2028. As part of that move, the Swiss pharma intends to end small-volume production of biologics at the Kleinbasel site and support it at other biologics sites within the company's global production network, according to the announcement.

Novartis noted that relocating laboratories to Basel is part of a previously announced plan to build a new biologics technical development center on the company's Basel campus to complement an existing biologics research center.

The Switzerland layoffs are the latest in a series of workforce cuts at the pharma this year. Most have affected Novartis' East Hanover, New Jersey, team. To date, the company has let go of 572 people at that location. Also, in May, Novartis disclosed plans to close a production facility in Wehr, Germany, affecting around 220 jobs, and confirmed to BioSpace it was laying off a "select number" of employees within its biomedical research organization. In total, Novartis has announced or disclosed in 2026 that it could let go of at least 922 people.

Arsenal BiosciencesSept. 2

Arsenal Biosciences is implementing a "significant strategic shift" to focus efforts on the development of in vivo CAR T therapies—a process that will involve a dramatic reduction in the company's workforce.

Ninety-nine employees will lose their jobs at the company's South San Francisco headquarters and Hayward, California, locations, a spokesperson for ArsenalBio confirmed to BioSpace via email on Aug. 31. This number represents "the majority of the company across all teams, functions, and locations." As of September 2025, ArsenalBio had 127 employees after downsizing by 50%. The spokesperson did not specify how many people will be left at the company after the latest round of layoffs.

As part of the strategic shift announced Aug. 31, ArsenalBio will be left with "a core team" of people who will work to advance the in vivo strategy while also looking for strategic alternatives for the company's assets and technologies.

ArsenalBio sacrifices 'majority' of staff in pivot to in vivo CAR T

After downsizing by 50% last year, Arsenal Biosciences is again laying off employees. This time, 99 people are getting cut as part of a strategic shift to focus the company's R&D efforts on in vivo CAR T therapies.

September 1, 2026

Tristan Manalac

CellaresSept. 1

In the wake of Bristol Myers Squibb terminating its partnership with Cellares, the manufacturing organization is again trimming staff, letting go of 68 employees in Bridgewater, New Jersey. The cuts will be effective Nov. 19, according to a Worker Adjustment and Retraining Notification (WARN) Act notice.

Last month, Cellares disclosed it was laying off 100 people in South San Francisco, where the company is headquartered. Those cuts are effective Oct. 20, according to a WARN alert. This brings the total known number of people being let go in the past few weeks to 168.

BMS ended its partnership with Cellares after finding the manufacturing organization's cell therapy system did not meet necessary requirements to make the CAR T cell immunotherapy Breyanzi. Cellares told BioSpace in an emailed statement that it "strongly disagrees" with the pharma's characterization of its system.

Manufacturing

BMS ends Cellares pact over cell therapy production problems, triggering layoffs

Setbacks to efforts to use Cellares' automated platform to make an approved CAR-T cell therapy led BMS to terminate its partnership with the manufacturing specialist.

August 26, 2026

Nick Paul Taylor

CellaresAug. 25

After losing a "large pharmaceutical customer," cell therapy manufacturer Cellares is undergoing layoffs, the company's CEO, Fabian Gerlinghaus, wrote in a LinkedIn post.

While Gerlinghaus did not disclose the identity of the customer, Cellares had previously announced a string of partnerships with Big Pharma Bristol Myers Squibb, including a $380 million deal inked in 2024. Endpoints News confirmed on Tuesday that BMS was the partner in question.

BMS determined that the Cellares' Cell Shuttle system "could not meet the necessary requirements" to make commercial batches of Breyanzi, one of its CAR-T therapies, a company spokesperson told the publication on Tuesday.

The CEO also didn't share how many workers would be receiving pink slips. According to a WARN document obtained by Biopharma Dive, 100 people are being let go.

Kolon TissueGeneAug. 19

Cell and gene therapy biotech Kolon TissueGene is parting ways with 37 employees at its Rockville, Maryland, site, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. The move comes after a pivotal Phase 3 failure for its cell therapy, TG-C, in osteoarthritis of the knee. The layoffs are expected to take place by Aug. 31, according to the notice.

ACTiVION-II, the first of two U.S.-based Phase 3 trials, did not meet the co-primary endpoints of VAS pain score and WOMAC total score at month 12, the company announced in a July 20 press release.

In a video statement on its website, Kolon TissueGene CEO Seng Ho Jeon apologized to the company's investors, acknowledging that the miss "caused great disappointment and concern."

The layoffs are "part of a broader realignment of our business and operational priorities," a TissueGene spokesperson told Fierce Biotech on Tuesday.

EMD SeronoAug. 18

EMD Serono, Merck KGaA's U.S. division, is letting go of 20 employees at its EMD Serono Research & Development Institute in Billerica, Massachusetts. The cuts are effective Oct. 16–30, according to a Worker Adjustment and Retraining Notification (WARN) Act notice.

The layoffs are separate from EMD Serono's move to bring 70 remote positions at the institute on site for at least three days per week starting in early September, as detailed in a July WARN alert. That decision could result in some employees resigning and receiving severance offers. An EMD spokesperson on Aug. 17 declined to say how many have resigned so far, telling BioSpace, "We don't share specific details on employee-related matters at the company."

The 20 employees being let go in October work in various areas of the institute and include four associate directors and a global program head. A company spokesperson told Fierce Biotech the decision best supports EMD Serono's research and development approach and future needs, adding that they plan to share additional details on that approach in the coming months.

Sanofi/Blueprint MedicinesAug. 17

About a year after closing its $9.5 billion acquisition of Blueprint Medicines, France-based Sanofi disclosed Blueprint is letting go of 229 employees in Cambridge, where the subsidiary is headquartered. The cuts are effective Oct. 9, 2026, to June 25, 2027, according to a Worker Adjustment and Retraining Notification (WARN) Act notice.

Blueprint, which is developing medicines focused on allergy/inflammation and oncology/hematology, had 687 employees as of April 2025, according to an SEC filing, meaning the layoffs could affect around 33% of its workforce.

Sanofi announced its acquisition of Blueprint in June 2025 and completed it one month later. The deal gave the pharma ownership of Blueprint's early stage immunology pipeline and Ayvakit, a therapy for the treatment of systemic mastocytosis. The rare blood disorder causes too many mast cells to build up in the body, affecting skin and internal organs.

MindMazeAug. 13

Switzerland-based MindMaze Therapeutics is letting go of "a handful" of Relief Therapeutics employees following the companies' reverse merger, a MindMaze executive confirmed to BioSpace.

"It has been our intention for some time to dispose of Relief's legacy operations and focus the company on its core neurology business," MindMaze Chief Financial Officer Jeremy Meinen said in an emailed response regarding the company's completion of a previously announced "organizational simplification."

In December, NeuroX Group SA and Relief Therapeutics completed a business combination that formed MindMaze Therapeutics, a publicly listed digital neurotherapeutics company that combined NeuroX's brain health platform with Relief's specialty biopharmaceutical portfolio.

Relief's legacy operations were based at one location in Switzerland, where about 25 employees worked, Meinen said. Rather than closing those operations, MindMaze found acquirers for those businesses, allowing "substantially all" Relief employees to retain their roles under new ownership, with some remaining at MindMaze, he explained. A handful of Relief employees are being let go and received notice periods of several months, meaning their end dates are in the future, Meinen said. He declined to provide additional details or name the businesses that acquired Relief's legacy operations.

Aardvark TherapeuticsAug. 13

Aardvark Therapeutics is down to 28 employees and 27 full-time or part-time consultants as of July 31, according to the biotech's second quarter securities document filed Aug. 11. Layoffs occurred in June, Aardvark confirmed in its second quarter earnings release on Aug. 11.

Aardvark had 40 employees and 35 consultants at the end of April.

In June, Aardvark also decided to discontinue of the Phase 3 HERO trial of ARD-101, an investigational asset for hyperphagia in Prader-Willi syndrome, according to the company's Q2 report. In May, the FDA placed ARD-101 under clinical hold amid cardiac signals in a healthy volunteer study, in which patients were given the drug at above therapeutic levels.

Aardvark is analyzing data from HERO, which it says could help determine the next steps for the candidate.

Aura BiosciencesAug. 11

As Aura Biosciences focuses resources on its ocular oncology programs, the biotech is cutting about 20% of its workforce, the company announced Aug. 11. The Boston-based company had 113 employees as of Feb. 28, meaning the layoffs could affect around 23 people.

Aura is working to advance clinical development of belzupacap sarotalocan, or bel-sar, in metastases to the choroid (the layer of the eye between the retina and sclera) and cancers of the ocular surface. The company's recent business highlights include completing enrollment in the Phase 3 CoMpass trial of bel-sar for early choroidal melanoma. Aura expects topline data from the 15-month primary endpoint in the second half of 2027.

In other business updates, the biotech shared that it's minimizing resource allocation toward its non-muscle invasive bladder cancer program and has made several leadership changes. Tony Gibney is stepping down as chief financial and business officer and Conor Kilroy is leaving his role as chief legal officer. Mark Plavsic has also departed from his position as chief technology officer. Aura has named Susan Abu-Absi as chief operating officer, Erica Kratz as chief regulatory and quality officer and Julie Person as chief people officer.

Aura expects cash payments and costs related to its organizational realignment and workforce reduction will be $2.9 million to $3.2 million, paid out mostly in the third quarter, according to an SEC filing. The company projected the changes it's making will extend its cash runway into the first half of 2029.

SchrödingerAug. 11

Schrödinger has laid off an unspecified number of employees as part of a shift in how it develops therapeutics, according to a written statement the company provided to BioSpace.

The biotech's second quarter earnings showed a Q2 reorganization expense of $279,000 representing restructuring costs, including severance payments and employee benefits. When asked about that restructuring, New York–based Schrödinger told BioSpace in a statement that as part of the company's ongoing business strategy, it made "targeted workforce changes" to better align resources with long-term plans and priorities.

"These changes," the statement continued, "reflect our strategic shift away from independent internal clinical development and toward securing development and commercialization partnerships, while continuing to advance and develop breakthrough technology that supports molecular discovery. As a result, the limited workforce reductions were concentrated within the team supporting our internal clinical development efforts."

Schrödinger, which uses a proprietary computational platform to help with drug discovery, has an internal pipeline consisting mainly of programs in the discovery or preclinical stage. Most programs target oncology, inflammation and immunology. The biotech is also working on collaborative drug discovery with companies including Bristol Myers Squibb, Eli Lilly, Novartis and Takeda.

The company did not provide additional details about the layoffs such as how many employees the job cuts affected. Schrödinger also had a workforce reduction last year. It announced in May 2025 it would let go of 60 employees to reduce its cash burn rate. As of Feb. 3, Schrödinger had 850 full-time staffers, according to an annual report.

aTyr PharmaAug. 10

To help focus resources on advancing its lead asset, aTyr Pharma will cut about 60% of its workforce, the company announced Aug. 9. The move will leave the San Diego–based biotech with about 20 employees, according to a related SEC filing. aTyr began notifying employees Aug. 7.

The biotech, which is developing therapies focused on fibrosis and inflammation, is working to advance lead asset efzofitimod in interstitial lung disease (ILD), which causes inflammation and scarring in the lungs. aTyr is awaiting feedback from the FDA on the protocol for a planned Phase 3 study of the therapy in pulmonary sarcoidosis and is working to complete a Phase 2 trial in systemic sclerosis–related ILD. The biotech expects the FDA's input by the end of this month.

aTyr's workforce changes include Chief Financial Officer Jill Broadfoot and General Counsel Nancy Denyes stepping down Sept. 30 and transitioning to consultant roles. Brandon Yaras, vice president of finance, will become CFO Oct. 1.

The biotech estimates it will incur costs of about $4.2 million in severance, employee health benefit obligations and other related termination benefits. aTyr expects the restructuring and additional cost-saving measures will cut annualized operating expenses by about $13 million and extend its cash runway into late 2028.

Arpeggio BiosciencesAug. 10

Arpeggio Biosciences decided last month to wind down, CEO Joey Azofeifa announced in a LinkedIn post. The Boulder, Colorado–based biotech had around 13 employees, based on LinkedIn profiles listing the company as an employer.

Arpeggio's lead drug program, a small molecule NRF2 degrader for non-small cell lung cancer, began to unravel over the past few months, Azofeifa shared in his post. In the end, he said, "we were unable to separate the molecule's efficacy from an off-target liability."

Azofeifa also noted Arpeggio's accomplishments, including generating over 50 million experiments in dozens of reporter lines incubated with a library of more than 150,000 compounds, sequencing over 300,000 transcriptomes and making more than 2,000 proprietary small molecules across four drug programs.

"Arpeggio's founding idea was beautiful," Azofeifa wrote. "We thought of biology as a deeply interconnected web and our goal was to develop medicine to restore the system rather than ablate a single target. There are numerous challenges associated with conceiving of drug discovery in this way, but this perspective left me in a perpetual state of awe. I'm grateful to have felt so small against the complexity of molecular biology."

EnsomaAug. 7

For the second time in less than a year, Ensoma is trimming its workforce. The Boston-based biotech confirmed the layoffs to BioSpace in a written statement Aug. 7. In addition, Ensoma is pausing investment and work for programs other than its lead asset while it pursues additional financing, according to a company spokesperson.

"Ensoma has undertaken an organizational restructuring to align our company and resources behind the continued development of EN-374 for X-CGD and clinical validation of its platform for additional therapeutic areas," the biotech noted in its statement.

Ensoma did not provide further details about the layoffs, including the number of affected employees. The biotech last cut its workforce in November, letting go of 50% of its staff to "prioritize resources in the areas best poised to advance our mission," CEO Jim Burns announced at the time in a LinkedIn post. He later told Endpoints News 37 employees would remain with the company.

EN-374 is an in vivo hematopoietic stem cell–directed gene insertion therapy for the treatment of X-linked chronic granulomatous disease (CGD), a rare genetic condition in which white blood cells can't properly fight infections. Ensoma announced in December it had dosed its first patient in a Phase 1/2 clinical trial of EN-374.

Ensoma's now-paused programs were in the research stage of development. One focused on sickle cell disease, another on solid tumor immuno-oncology and the last on heme oncology.

Emergent BioSolutionsAug. 6

To align resourcing to current needs, Emergent BioSolutions is restructuring its business, a move that includes letting go of 93 employees across the company and eliminating 21 vacant positions. Emergent announced the plans in its second quarter earnings release and provided additional details in a related SEC filing.

The layoffs represent a small number of the company's overall workforce, which was about 900 employees as of Dec. 31, 2025.

Emergent, which develops and manufactures medicines for diseases including smallpox and makes Narcan, which treats opioid overdoses, did not specify which locations the workforce reduction will affect. However, the announcement noted the closure of wet laboratories in Gaithersburg, Maryland, where the company is based.

The restructuring includes eliminating the role of chief medical officer, head of research and development, pushing Simon Lowry out of Emergent effective Aug. 19. The company is also creating a new "growth organization" that combines research and development, business development and strategy into one function. Stephanie Duatschek will lead that team in her new role as executive vice president, chief growth officer. Previously, she was senior vice president, chief global strategy and franchise development officer.

Emergent expects to incur costs of $10 million to $11.5 million in connection with the restructuring. As of June 30, the company's capital resources included $139.7 million in cash and cash equivalents.

Aurora TherapeuticsAug. 6

Aurora Therapeutics has joined the growing list of companies struggling to create N-of-1 therapies for ultrarare genetic diseases. The fledgling biotech is parting ways with both its lead gene editing program and "several" staffers.

Aurora launched in January with $16 million in seed capital from Menlo Ventures and an initial focus on phenylketonuria (PKU), a rare, inherited disorder in which the body is unable to break down the amino acid phenylalanine. Toxins can then build up, leading to neurological complications.

However, Aurora has since encountered competition in the PKU space, a company spokesperson told BioSpace Aug. 4.

"We have decided to deprioritize the PKU program as others in the field have started their own programs," the spokesperson said in an email. "As part of that, several team members were unfortunately let go."

Bespoke gene-editing outfit abandons lead program, cuts 'several' employees

Seven months after launching with $16 million in seed financing, Jennifer Doudna's Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in the field.

August 5, 2026

Heather McKenzie

PfizerAug. 5

Pfizer is adding $2.5 billion in cuts to an ongoing restructuring, with much of the new reduction coming in the form of "technology and simplification efforts" across the New York pharma's commercial, R&D and manufacturing functions.

The cuts that fall under Pfizer's "Realigning Our Cost Base Program" will save an anticipated $1 billion, Pfizer announced Aug. 4 in its second quarter earnings release. The savings will primarily occur between 2027 and 2029, although they don't come for free. Under the program, Pfizer will incur a one-time cost of $2 billion for "digital enablement, implementation and severance," the pharma said.

A company spokesperson declined to provide additional details on how the severance will be paid out, whether any jobs will be affected and what technological changes are being made.

Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure

The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major products like the blood thinner Eliquis.

August 4, 2026

Annalee Armstrong

Lisata TherapeuticsAug. 5

With a planned merger with Kuva Labs now off the table, Lisata Therapeutics has slashed about 72% of its full-time workforce and filed a lawsuit against Kuva, the biotech announced Aug. 4. The Basking Ridge, New Jersey–based company had 21 full-time staffers as of Dec. 31, 2025, meaning the cuts could affect around 15 people.

The layoffs were necessary to reduce operating expenses and preserve cash to pursue strategic alternatives, according to Lisata, which is developing therapies for the treatment of advanced solid tumors and other serious diseases. Those out of jobs include Kristen Buck, executive vice president of research and development and chief medical officer, as noted in an SEC filing.

Lisata's lawsuit against Kuva alleges that Kuva breached the merger agreement, according to the announcement. Lisata is seeking damages for the benefit of its stockholders and a $2 million termination fee it says it's owed under the agreement.

Lisata axes 72% of workforce following failed merger with Kuva

In addition to laying off employees, including a member of its management team, Lisata Therapeutics is also suing Kuva Labs, alleging the company breached a merger agreement.

August 4, 2026

Angela Gabriel

Supernus Pharmaceuticals and Indivior PharmaceuticalsAug. 4

Supernus Pharmaceuticals and Indivior Pharmaceuticals' merger into one central nervous system–focused company will likely lead to "natural redundancies" among general and administrative roles, Supernus CEO Jack Khattar said during an investor call Aug. 3. No further details were provided in the call, a press release or related SEC filings.

As of Dec. 31, according to their annual reports, Rockville, Maryland–based Supernus had 778 employees, while North Chesterfield, Virginia–based Indivior had 838.

The all-stock merger of equals will combine the two companies' revenue for an expected yearly revenue of $2.2 billion. Of that, Supernus and Indivior expect to collect around $888 million in operating earnings.

Supernus and Indivior merge to create CNS mega-company with 11 approved drugs

Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”

August 3, 2026

Gabrielle Masson

GSK’s $2.5 billion restructuring over the next three years will include global job cuts, the company announced in a July 29 media call. CEO Luke Miels declined to say how many employees the U.K. pharma will let go.

“We’re not going to give a number today in terms of people changes, and that’s because I want the chance, and I want my team to have the chance, to discuss this with our people first,” Miels said. “I think the key theme, as I’ve said, is it’s about reallocation into new medicines, but we will update you in time once we’ve implemented those plans.”

GSK intends to use the expected savings in part to keep funds flowing into its late-stage portfolio and pipeline. Some funds will also go toward improving margins and profitability amid HIV medicine dolutegravir’s patent expiry in the U.S. in 2028.

GSK shares rise as $2.5B cost-cutting plan unveiled

As GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.

July 28, 2026

Gabrielle Masson

AmgenJuly 27

Amgen is letting go of around 40 employees, a spokesperson confirmed to BioSpace July 24 via email. They declined to comment on which positions or locations are affected.

“As part of our ongoing efforts to align our operations with our strategic objectives, we are making organizational changes that have impacted certain roles,” the spokesperson said. “We are committed to supporting our employees through this transition.”

The Thousand Oaks, California–based pharma made headlines recently amidst FDA and European Medicines Agency recommendations to withdraw rare disease drug Tavneos from the market. In January, the FDA cited liver toxicity issues that affected the overall risk-benefit profile of the drug, which was approved in 2021 for ANCA-associated vasculitis (AAV). In May of this year, news broke that 20 patients in Japan had died after taking Tavneos.

In a July 24 statement, Amgen said it strongly disagrees with the FDA’s proposal to withdraw the drug from the U.S. market. The company has requested a meeting with the agency to discuss Tavneos’ future.

Amgen deploys patients to defend troubled Tavneos in FDA hearing request

Facing pressure around the world to withdraw the rare kidney disease drug Tavneos, Amgen has launched a robust defense with real-world evidence to support the product’s benefit-risk profile.

July 24, 2026

Annalee Armstrong

CLINUVEL PHARMACEUTICALSJuly 23

As part of a strategic reorganization to focus operational resources on the U.S. market, CLINUVEL PHARMACEUTICALS will cut its global workforce by 10% to 20%, the company announced Thursday. CLINUVEL had 104 employees as of June 15, according to an SEC filing, meaning the layoffs could affect as many as 21 employees.

The biopharma, which develops therapies for patients with genetic, metabolic and dermatological disorders, will relocate its headquarters from Australia to New York at the start of 2027. The move is meant to boost CLINUVEL's regulatory engagement and commercial partnerships, according to the announcement. Regarding commercialization, the company noted that its late-stage programs, especially in vitiligo, are primarily targeted at the U.S. patient population, which it estimates at approximately 6 million affected.

CLINUVEL's workforce reduction reflects a necessary realignment of operating expenditure with current revenue generation and near-term clinical and commercial priorities, according to the announcement. The company also highlighted that the restructuring is a prerequisite to unlocking deeper, more liquid capital pools in the U.S.

EMD SeronoJuly 13

EMD Serono, the U.S. healthcare unit of Germany's Merck KGaA, may cut up to 70 employees who report to its EMD Serono Research & Development Institute site in Billerica, Massachusetts. Effective in early September, the company will require those R&D staffers to work in the office at least three days per week, which could result in some resigning and receiving severance offers, according to a Worker Adjustment and Retraining Notification (WARN) Act alert for the state.

Remote employees living more than 50 miles from the Billerica site have been given the option to commute to work from their residence, relocate closer to the institute with company-provided relocation support or resign. EMD Serono expects the effective dates for those who choose the third option will be Sept. 4 but noted that due to business needs, some will have a later separation date.

The company previously laid off workers in January, though it kept the exact number of affected people under wraps. This headcount reduction round affected its research workforce in Durham, North Carolina.

EMD Serono's parent Merck KGaA posted a 2.9% year-on-year growth in the first quarter to bring in €5.1 billion (around $5.83 billion) worldwide. Its healthcare business, which covers drug development and medical devices, earned €2.1 billion ($2.4 billion), a 3.4% decline from the previous year.

Correction: BioSpace updated this entry July 13 after receiving the full WARN notice, which clarified the layoffs were not a certainty for all 70 employees and that any cuts would result from staffers resigning. BioSpace regrets the error.

NovartisJuly 8

In its largest round of layoffs this year, Novartis is trimming its East Hanover, New Jersey, workforce for a fourth time, letting go of 322 employees and bringing the total number of affected people at that location to 572. The cuts are effective Oct. 2, according to a Worker Adjustment and Retraining Notification (WARN) Act notice.

The first three rounds of layoffs at the Swiss pharma's East Hanover location were disclosed in March, April and May, affecting 114, 60 and 76 employees, respectively. All cuts are effective this year.

In total, Novartis has announced or disclosed in 2026 that it is letting go of at least 792 employees. In May, the pharma confirmed to BioSpace it is laying off a “select number” of staff within its biomedical research association. That same month, the company announced it will shut down a production site in Wehr, Germany by the end of 2028, eliminating 220 jobs.

Novartis slashes New Jersey workforce again, cutting 322 employees

With the latest layoffs, Novartis expects to let go of around 800 employees by the end of 2028. More than half of the cuts have been at the company’s East Hanover, New Jersey, location.

July 7, 2026

Angela Gabriel

GenentechJuly 6

The extent of Genentech’s June cuts has become clearer. The South San Francisco–based biotech is laying off 103 people at its headquarters effective July 29, according to a Worker Adjustment and Retraining Notification (WARN) Act notice dated June 26 and processed July 1.

The cuts affect not only Genetech’s research and early development group (gRED), as reported last month, but also other parts of the business, according to a company statement emailed to BioSpace.

“It is important to emphasize that most of these are focused adjustments within Genentech impacting a small proportion of the organization, and we continue to hire within Genentech, including gRED,” the statement noted. “Our hiring approach reflects the capabilities, expertise, and areas of science that are most critical to advancing our portfolio and delivering transformative medicines to patients now and in the future.”

The June adjustments included the departure of high-profile executive Vishva Dixit, who had been with Genentech since 1997. He most recently served as vice president and senior fellow, physiological chemistry, research biology.

Genentech R&D layoffs hit top exec who’s been with the biotech nearly 30 years

The staffing changes will focus resources on work that creates the highest impact for patients, according to Genentech. The number of employees affected is unknown, but longtime veteran Vishva Dixit is out.

June 11, 2026

Angela Gabriel

BioNTechJuly 6

BioNTech will shutter Berlin-based subsidiary JPT Peptide Technologies by the end of this year, affecting around 140 positions, as it sharpens focus on growing its late-stage oncology pipeline, according to a quarterly report. JPT is a contract manufacturing company specializing in peptide-based products and services.

Germany-based BioNTech is also shutting down manufacturing facilities in Idar-Oberstein and Marburg, Germany, and CureVac’s sites in Germany and abroad by the end of next year and a Singapore facility by Q1 2027. Those closures will affect about 1,860 jobs.

Editor’s note: BioSpace updated this entry July 6 after receiving a response from BioNTech regarding the JPT closure, including why the site is shuttering.

BioNTech moves to close multiple manufacturing plants, affecting 1,860 jobs

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

Nick Paul Taylor

BioCrystJune 29

BioCryst is moving away from internal discovery work, a strategic shift that includes shuttering an Alabama site by the end of 2026. A company spokesperson declined to comment on how many employee roles will be impacted by the shutdown. Instead of working on its own discovery programs, BioCryst said it will focus on external innovation.

“We are committed to supporting everyone affected through this transition,” the spokesperson told BioSpace on June 29. “Our commercial business and clinical programs are unaffected and continue as planned.”

The impacted location is BioCryst’s Discovery Center of Excellence in Birmingham, Alabama. The strategic decision was made about a month after the company culled its diabetic macular edema candidate avoralstat that was being evaluated in a Phase 1b trial to focus on its rare disease pipeline.

BiogenJune 26

Biogen is letting go of a “small number of roles” within its research arm related to discontinued Apellis Pharmaceuticals programs, the company told BioSpace in an email.

Biogen did not share specific figures related to the number of people it would be laying off.

In March, the biopharma announced its $5.6 billion takeover of Apellis, delivering two approved medicines—Empaveli and Syfovre—and a team with the know-how to lay a path for the launch of Biogen’s own late-stage kidney candidate.

“As part of the integration of Apellis, Biogen is conducting a comprehensive review of the former Apellis clinical & preclinical portfolio to further evaluate strategic fit,” a Biogen spokesperson told BioSpace.

“As a result of this ongoing review, Biogen made the decision to pause or terminate investment in the majority of legacy Apellis pre-clinical programs,” the spokesperson added.

ADC Therapeutics

After 27 deaths were reported in a clinical trial arm receiving its blood cancer drug Zynlonta, ADC Therapeutics is conducting a 17% workforce reduction.

The Swiss biopharma employed 188 full-time workers and five part-time staffers as of Dec. 31, 2025, according to an annual filing, meaning the cuts will likely impact around 32 roles.

The company said the cuts are designed to save $10 million per year, though the terminations will cost ADC Therapeutics around $3 million in severance, benefits and related expenses.

The reorganization was prompted by the anticipated completion of the LOTIS-5 Phase 3 and LOTIS-7 Phase 1b trials for Zynlonta, according to the company. The anti-CD19 antibody-drug conjugate (ADC) won accelerated approval in 2021 for relapsed or refractory diffuse large B cell lymphoma (DLBCL) in third-line or later settings, and LOTIS-5 is supposed to serve as a confirmatory trial.

But the trial, which tested Zynlonta plus rituximab, demonstrated no overall survival benefit. Additionally, 27 patients in the Zynlonta arm died, compared to nine deaths in the control group.

Since the data drop, the biopharma's stock has crashed 66%.

ADC Therapeutics lays off staff after 27 patient deaths mar Zynlonta readout

After 27 deaths were reported in a group receiving its blood cancer drug, ADC Therapeutics is downsizing, implementing layoffs for about 30 workers.

June 24, 2026

Gabrielle Masson

Sangamo TherapeuticsJune 23

In conjunction with filing for bankruptcy, Sangamo Therapeutics is laying off 51 people.

The workforce reduction represents about 40% of the biotech's team, according to an SEC filing.

Sangamo is retaining 77 staffers who will continue work on programs and platforms that Eli Lilly and Astellas have placed stalking horse bids on, including a rare disease gene therapy that is in the process of being submitted for FDA review.

June 23, 2026

Gabrielle Masson

Tourmaline BioJune 23

Tourmaline Bio said goodbye to 60 employees at its New York headquarters months after being swallowed by Novartis.

The workforce reduction stems from the closure of a Tourmaline site at 27 West 24th in New York, according to a Workers Adjustment and Retraining Notification (WARN) alert for the state. The layoffs took effect May 29, though the notice was only posted last week.

Novartis moved to acquire Tourmaline in September last year, putting around $1.4 billion on the line on a fully diluted basis, the pharma said at the time. The transaction closed in late October.

Novartis has conducted several rounds of layoffs this year, including one that takes effect in August and will leave 76 New Jersey workers jobless. The pharma also announced in May that it would shutter a Germany facility by the end of 2028, which will affect 220 jobs. Novartis ran two other cycles of terminations—one in March and another in April—which together affected more than 170 staff in New Jersey.

enGene TherapeuticsJune 16

Genetic medicines developer enGene is halving its workforce in an attempt to save cash.

As of October 2025, the biotech employed 82 full-time staffers, according to an annual report, meaning the cuts may impact more than 40 people.

Alongside the 50% workforce reduction, three C-suite members are hitting the exits, according to a June 15 release.

Ultimately, the company hopes to start a Biologics License Application (BLA) submission with the FDA in the second half of this year for its sole clinical candidate detalimogene voraplasmid. The non-viral gene therapy is being evaluated in the Phase 1/2 LEGEND trial for patients with non-muscle invasive bladder cancer. enGene is planning a potential commercial launch for next year.

“To preserve shareholder capital as we await additional durability data and meetings with the FDA, we made the very difficult decision to downsize the organization to streamline operations,” enGene CEO Ron Cooper said in a prepared statement.

Neumora TherapeuticsJune 16

Neumora Therapeutics is discarding its most advanced drug candidate after two late-stage fails, prompting the biotech to lay off 35% of its workforce in an effort to save cash.

As of the end of last year, Neumora had 96 full-time employees, according to the company’s annual filing, meaning the cuts could affect more than 30 employees. More than half of the biotech’s staff is primarily engaged in R&D.

The reduction, which is expected to occur in the second and third quarters of this year, is projected to save the company around $10 million annually.

GenentechJune 12

Genentech has made changes to its research and early development group (gRED) that include parting ways with a high-profile executive who had been with the company since 1997. The South San Francisco–based biotech confirmed to BioSpace the “targeted adjustments” and departure of Vishva Dixit, who most recently served as vice president and senior fellow, physiological chemistry, research biology.

The restructuring is intended to ensure the Roche subsidiary’s capabilities and investments align with its core therapeutic areas, advance its portfolio and deliver transformative medicines to patients faster, according to Genentech. A spokesperson declined to share specific information about the layoffs, including how many employees were affected.

Endpoints News reported that Genentech is closing infectious disease and physiological chemistry units while downsizing other teams. Also, in addition to Dixit, other key departures include Todd McDevitt, vice president and head of cell therapy, and Man-Wah Tan, a vice president and senior fellow of infectious diseases, the media outlet reported.

Genentech R&D layoffs hit top exec who’s been with the biotech nearly 30 years

The staffing changes will focus resources on work that creates the highest impact for patients, according to Genentech. The number of employees affected is unknown, but longtime veteran Vishva Dixit is out.

June 11, 2026

Angela Gabriel

Teva PharmaceuticalsJune 11

Teva Pharmaceuticals is letting go of 250 employees from its active pharmaceuticals ingredient (API) division, according to various media reports. The cuts will take place over the next two years and affect employees in Israel, according to domestic news outlet Globes.

Teva's API unit has around 4,100 employees worldwide, including 650 in Israel. In January 2024, Teva revealed it planned to divest its API business to allow the overall company to "maximize current and potential revenue streams."

In October 2025, Teva was reportedly in advanced negotiations for the sale of the API unit, according to European Pharmaceutical Review. A month later, the company said talks with the selected buyer were terminated.

Fulcrum TherapeuticsJune 10

Just days after announcing it was exploring strategic alternatives for the business after ending development of its lead asset, Fulcrum Therapeutics is cutting 85% of its workforce, according to an SEC filing. The Cambridge, Massachusetts–based biotech will lay off 48 of its 57 employees as part of a restructuring plan approved May 31 meant to significantly reduce operating expenses and preserve capital. Fulcrum informed staff on June 4.

The company announced June 1 it is discontinuing development of pociredir in sickle cell disease, as it no longer sees a viable regulatory path for the drug. Fulcrum noted that the FDA had recently raised concerns regarding pociredir's benefit-risk profile in that indication.

The biotech expects to mostly complete its layoffs during the second quarter. Fulcrum estimated it will incur about $4.2 million in costs in connection with its restructuring plan, consisting mostly of severance, benefits and related expenses.

Sickle cell disease

Fulcrum lays off 85% of staff after dropping asset, leaving 9 employees

After discontinuing development of its lead asset, Fulcrum Therapeutics has provided more details on its restructure, with 48 of 57 employees headed out the door.

June 5, 2026

Tristan Manalac

Merck is again sending employees packing in Rahway, New Jersey. The pharma is laying off 88 employees at its location there effective Sept. 4, according to a Worker Adjustment and Retraining Notification Act notice. Last year, Merck disclosed it was letting go of 262 employees in Rahway over two rounds of cuts, one of which took effect this year.

In August 2025, the pharma divulged it was laying off 58 people at that site on Nov. 14. The news came shortly after Merck confirmed that its $3 billion cost-cutting move could affect about 6,000 employees as part of a multiyear process. In November, the pharma disclosed it would let go of 204 staffers in Rahway from Feb. 20 through May 11.

In February 2026, Merck then disclosed in a WARN notice that it would lay off 154 employees in Durham, North Carolina, on May 1.

Johnson & JohnsonMay 27

New Jersey's job market is taking another hit, this time from pharma giant Johnson & Johnson, which is parting ways with 56 employees in New Brunswick, according to a Worker Adjustment and Retraining Notification (WARN) Act posting for the state. The layoffs will take effect on August 21.

This is J&J's first announced workforce reduction of this year, according to a tally by BioSpace. But the pharma has for years been constantly reshaping its business to accommodate the loss of exclusivity of its autoimmune disease powerhouse Stelara—a campaign that has involved cutting back investments in other parts of its business, while putting more money into higher-value areas like cancer.

Other Big Pharma players to recently slash their New Jersey headcounts include Novartis, Bristol Myers Squibb and Novo Nordisk.

NovartisMay 22

Novartis is continuing to trim its workforce in the U.S., letting go of 76 employees in East Hanover, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) Act alert for the state. The layoffs will take effect on Aug. 21.

This will be the third time this year that Novartis downsized its New Jersey operations. The first batch of layoffs was announced in March, affecting 114 employees set to take effect from June 26 through Nov. 27. The second hit came a month later, with 60 jobs projected to be cut from July 24 through Nov. 20.

Novartis earlier this month also announced that it would close down a production site in Germany by the end of 2028, eliminating 220 jobs in the process.

AbbVieMay 22

AbbVie's operations in Irvine, California, will be 85 employees leaner after July 20, with layoffs projected to take place on that date, according to a Worker Adjustment and Retraining Notification (WARN) Act alert.

The pharma has over 40 open posts available in California, including data science and biologics product development listings. A recent BioSpace report found that AbbVie CEO Robert Michael saw a 76% pay bump, with his total compensation package reaching $32.5 million last year as compared to $18.5 million in 2024.

As per BioSpace's tally, this is the first time AbbVie has announced layoffs this year.

NovartisMay 15

Novartis is letting go of "a select number" of employees within its biomedical research organization, a company spokesperson confirmed to BioSpace in an emailed statement.

"Novartis continually assesses opportunities to support our growth strategy as a focused innovative medicines company," the statement read. "We regularly evaluate our organizational setup to ensure it remains aligned with evolving priorities."

The cuts are the latest in a series of made or projected layoffs at Novartis this year that in total affect nearly 400 employees. Earlier this month, the Swiss pharma announced plans to shutter a production facility in Wehr, Germany, by the end of 2028. Novartis expects that closure will eliminate 220 jobs. In March and April, the pharma disclosed between two Worker Adjustment and Retraining Notification (WARN) Act notices that it will let go of 174 employees in East Hanover, New Jersey. Of those cuts, layoffs affecting 114 people are effective June 26 through Nov. 27, while those impacting 60 staffers run from July 24 through Nov. 20.

TakedaMay 15

To cut back on costs, Takeda is rolling out a sweeping “transformation program” that will streamline corporate operations and see some 4,500 employees let go in fiscal year 2026, according to an earnings presentation. That number represents less than 10% of total roles globally and does not reflect hiring plans, a company spokesperson told BioSpace in an emailed response on May 13.

“Right now, we have 2,200 open roles globally and we expect to create new jobs throughout the year, which we are prioritizing filling with internal candidates,” the spokesperson said.

The layoffs will look different across the organization and will be phased according to unique business needs and country requirements, according to the spokesperson. They confirmed that the cuts include an estimated 247 roles in Massachusetts and 387 in other states outlined in a March Worker Adjustment and Retraining Notification (WARN) Act notice.

Takeda’s ‘transformation program’ leaves 4,500 jobless

While Takeda is eliminating 4,500 roles across its global operations, the company has some 2,200 jobs currently open for hiring, for which internal candidates will be prioritized.

May 14, 2026

Tristan Manalac

ValnevaMay 14

Specialty vaccine maker Valneva will trim its global workforce by 10% to 15% as it focuses resources on its base business and key strategic projects, the biotech announced May 13. The France-based company had 674 employees globally, including 22 in Bethesda, Maryland, as of Dec. 31, according to an SEC filing, meaning the layoffs could affect roughly 67 to 101 people.

Valneva expects the cuts will reduce 2026 operating expenses by 25% to 35% when compared to 2025.

The restructuring comes as the biotech reports a Q1 revenue decline. Total revenue was 30.9 million euros ($36.1 million), down from 49.2 million euros ($57.6 million) in the first quarter of 2025. Valneva attributed the dip in part to a planned winddown of third-party sales. The company also noted it is adjusting down its 2026 sales and revenue guidance in part because of “an emerging adverse trend in travel vaccine uptake across key markets, driven by geopolitical factors.” Valneva is revising the product sales guidance range from between 145 million euros and 160 million euros ($170 million to $187 million) to between 135 million euros and 150 million euros ($158 million to $174 million).

Valneva’s last known restructuring was in 2025. The biotech announced in November it would shutter its Nantes, France, site and consolidate operations in Lyon. That move left 30 employees jobless, a spokesperson told Fierce Biotech at the time.

Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint

The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% efficacy against the tick-borne disease in a Phase 3 trial—but failed to hit a predetermined confidence interval.

March 23, 2026

Heather McKenzie

Amicus TherapeuticsMay 13

Just two weeks after being completely absorbed into BioMarin Pharmaceutical, Amicus Therapeutics is letting go of 58 employees from its headquarters in Princeton, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) alert for the state. The layoffs will start on Aug. 7 and will run through Oct. 30 of this year.

A company spokesperson confirmed to Fierce Pharma that the job cuts are linked to the BioMarin acquisition. “As with any integration of this scale, we are carefully evaluating how to align our long-term success,” the spokesperson said. “This process has resulted in headcount reductions, particularly in areas where there is overlap.”

BioMarin moved to acquire Amicus in December 2025 for $4.8 billion.

Gilead SciencesMay 8

In the wake of closing its $7.8 billion Arcellx acquisition last week, Gilead Sciences is gutting the biotech’s workforce in California and Maryland, laying off 192 employees total. Given Arcellx had 220 employees as of March 1, according to an SEC filing last month, the cuts are likely wiping out 87% of the staff.

The largest cuts are happening at the biotech’s headquarters in Redwood City, California. Gilead is letting go of 108 employees at that site effective June 30, according to a Worker Adjustment and Retraining Notification (WARN) notice. The pharma is also laying off 84 people in Rockville, Maryland. Those cuts are taking place over a longer period, from June 30, 2026, to April 30, 2027, according to a WARN notice.

Both notices were dated April 30, two days after Gilead announced it had completed its acquisition of Arcellx, making the biotech a wholly owned subsidiary.

Gilead wipes out most of Arcellx workforce

Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder happening in 2027.

Angela Gabriel

NovartisMay 8

Novartis plans to close a production facility in Wehr, Germany, by the end of 2028, a move that’s expected to eliminate 220 jobs, the Swiss pharma announced May 5.

The site, which makes solid oral dosage forms such as tablets and capsules for mostly established Novartis products, is no longer competitive, the company noted in its announcement. Novartis said it remains committed to Germany as a business location.

The pharma is investing 35 million euros (about $41 million) into a new production facility for radioligand therapies in Halle, Germany. The site will produce personalized cancer therapies for patients in Germany and should be operational in 2027, according to the announcement.

Gilead SciencesMay 6

After closing its $7.8 billion takeover of Arcellx last week, Gilead Sciences is now letting go of 108 employees at the biotech’s headquarters in Redwood City, California, according to a Worker Adjustment and Retraining Notification (WARN) alert for the state. The layoffs will take effect on June 30.

Arcellx had 220 employees as of March 1, according to a securities filing last month, indicating that Gilead's cuts will nearly halve the biotech's workforce.

Gilead and Arcellx are long-time partners. The companies joined hands in December 2022, with the pharma paying $225 million upfront alongside a $100 million equity investment in the biotech. The deal was focused on Arcellx's late-stage CAR T therapy—the asset that would later be named anito-cel—for the treatment for relapsed or refractory multiple myeloma. Gilead at the time pledged up to $3.9 billion in milestones.

BioNTechMay 6

BioNTech has outlined plans to close multiple manufacturing facilities by the end of next year, affecting about 1,860 jobs.

The German biotech intends to shutter three facilities in its home country. BioNTech's Idar-Oberstein, Marburg and Tübingen sites are scheduled for closure by the end of next year. As previously disclosed, the biotech is also exiting a manufacturing facility in Singapore. BioNTech expects to conclude operations at the Singapore facility by the first quarter of next year.

Efforts to consolidate the manufacturing network are focused on sites where capacity will become idle or underused within 24 months, BioNTech CFO Ramón Zapata said on the company's first-quarter earnings call on May 5. BioNTech is exploring divestment options, including partial and total sales of the plants.

BioNTech moves to close multiple manufacturing plants, affecting 1,860 jobs

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

Nick Paul Taylor

Passage BioMay 5

Shortly after announcing that the FDA will require a specific registrational trial design for its lead drug candidate in one target indication, Passage Bio disclosed that it will cut about 75% of its workforce to reduce operating expenses. The Philadelphia-based biotech had 24 employees as of Dec. 31, according to an annual report, meaning the layoffs could affect around 18 people.

Passage, which focuses on developing genetic medicines to treat neurodegenerative diseases, expects to mostly complete the workforce reduction in the second and third quarters, according to an April 28 SEC filing. The biotech projects severance and exit costs will be about $3.3 million.

On April 20, Passage announced the outcome of a recent Type C meeting with the FDA regarding the design of a future registrational trial for PBFT02 for the treatment of frontotemporal dementia with granulin mutations (FTD-GRN). Will Chou, the company's president and CEO, said the agency did not support a single-arm trial design and instead will require a randomized controlled trial.

Passage cuts 75% of workforce after FDA trial design request

Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include frontotemporal dementia, is exploring strategic alternatives in addition to cutting staff.

Angela Gabriel

Reckitt BenckiserMay 1

After sustaining a 0.9% decline in North America sales in the first quarter, U.K.-based Reckitt Benckiser is letting go of 57 people from its office in Nutley, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) Act alert for the state. The layoffs started this March and will run until March next year.

Also in March, Reckitt trimmed its New Jersey workforce at its Parsippany site, letting go of 62 employees. Those layoffs will be conducted through August.

Reckitt is known for products like the expectorant Mucinex, the lozenge brand Strepsis and the nonsteroidal anti-inflammatory medicine Neurofen.

Autolus TherapeuticsApril 30

In a move aimed at improving operational efficiency and cutting costs, London-based Autolus Therapeutics is letting go of about 13% of employees, the company announced April 29. The biotech, which develops autologous CAR T therapies, did not identify which locations the workforce reduction will affect but noted that it will impact all areas of the business. Autolus has a U.S. presence through its Gaithersburg, Maryland, office.

While the company said it's cutting 13% of the workforce, it also noted that the reorganization includes "employee-related actions taken beginning in the second half of 2025." When asked to clarify that statement, a spokesperson told BioSpace in an email that some employees were let go in the second half of last year, but "the number didn't rise to the level of 'material' thus there was no announcement." Those cuts, they added, count as part of the 13%.

The spokesperson did not identify how many people were laid off in the second half of last year. Autolus had 752 employees as of Dec. 31, according to its 2025 annual report.

Autolus plans to mostly complete the latest cuts by the third quarter and to save about $15 million on an annualized basis beginning in 2027, according to the announcement. The biotech expects its current and projected cash, cash equivalents and marketable securities will fund operations into the fourth quarter of 2027. Autolus had cash and cash equivalents of $104.1 million and marketable securities of $196.6 million as of Dec. 31, according to its annual report.

NovartisApril 28

For the second month in a row, Novartis is chipping away at its East Hanover, New Jersey, workforce. The Swiss pharma is laying off 60 employees in the city effective July 24 to Nov. 20, according to a Worker Adjustment and Retraining Notification Act (WARN) notice. Novartis is also letting go of 114 people in East Hanover from June 26 to Nov. 27, according to a March WARN alert.

Novartis also trimmed its workforce in 2025, putting 1,069 employees—including 485 in East Hanover—on the chopping block over a multiyear period. The largest round of layoffs involved 550 employees in Switzerland who will be out of work by the end of 2027.

Tempero BioApril 24

On the heels of a serious adverse event in a Phase 2 alcohol use disorder trial of its lead drug candidate, Tempero Bio is shutting down, Endpoints News has reported. The Oakland, California–based biotech's CEO, Paul Johnson, told Endpoints he could not provide details about what happened with the study of TMP-301, which was being developed to address the neurobiological basis of addiction.

Tempero, which has between two and 10 employees, according to its LinkedIn page, launched following a 2020 partnership between investment firm Aditum Bio and Soshei Heptares, now Nxera. Aditum was co-founded by Joe Jimenez, a former Novartis CEO, and Mark Fishman, who once headed up the pharma's research and development hub, Novartis Biomedical Research.

The biotech made a significant funding announcement roughly a year ago. In March 2025, Tempero shared it had raised $70 million in Series B financing to develop therapies for substance use disorders. The company said it would use the funds in part to push TMP-301 through two Phase 2 clinical trials for alcohol- and cocaine-use disorders.

BIOSPACE · NOV 5, 2026

Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap

---

Evommune is commiting $30 million upfront for Hinova Pharmaceuticals' oral molecular glue degrader—a low-cost bet with a high probability of success, according to analysts, after clinical failures roiled the biotech's internal pipeline earlier this year.

Evommune is paying Hinova Pharmaceuticals $30 million to license the China biopharma's oral molecular glue degrader for autoimmune diseases.

The pact gives Evommune worldwide rights—excluding in the Greater China area—to a VAV1-directed candidate, with a mid-stage trial in rheumatoid arthritis slated to launch in 2027.

Evommune's upfront payment consists of $20 million cash and $10 million in pre-funded warrants to purchase Evommune stock, according to a Thursday release. Hinova could also garner up to $1.1 billion in milestone payments, plus royalties on net sales outside of China.

The molecular glue degrader, formerly called HC118 and known as HP570 in China, will now be called EVO570. Requests to begin clinical trials for the drug have been accepted in the U.S. and submitted in China, with a Phase 1 study expected to launch imminently.

EVO570 targets VAV1, a signaling protein mainly located in immune cells that drives T and B cell activation across several chronic inflammatory diseases, according to the companies. The molecular glue degrader is designed to eliminate VAV1, thereby improving safety and tolerability compared to JAK inhibitor treatments.

Oppenheimer analysts view the "low-cost/high-PoS [probability of success] deal as a major positive advancement" for Evommune, according to a Thursday investor note. As rationale, the analysts cited the creation of a near-term clinical catalyst and the potential for a first-in-class rheumatoid arthritis program, plus the possibility of expansion into neurological indications.

There are over 1.2 million U.S. patients with rheumatoid arthritis, a chronic condition that causes inflammation of the joints. The space carries "significant commercial opportunity that can accommodate multiple players," according to Oppenheimer. Currently, the only approved oral therapies for the condition are JAK inhibitors, which carry boxed warnings for serious safety risks, such as mortality and thrombosis.

In preclinical studies, EVO570 demonstrated 20 times more potency than Novartis' oral molecular glue degrader MRT-6160, according to Oppenheimer. Novartis picked up MRT-6160 from Monte Rosa Therapeutics in 2024 for $150 million upfront and up to $2.1 billion biobucks. The asset is currently in mid-stage development for psoriatic arthritis and Sjögren's disease.

Importantly, the freshly penned deal addresses Evommune's "catalyst vacuum" after its oral asset EVO756 missed in mid-stage studies for both chronic spontaneous urticaria and atopic dermatitis. Development of the candidate in both indications has been discontinued, though the biotech continues to study the asset in a mid-phase migraine trial.

Immunology and inflammation

Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes

With the failure in chronic spontaneous urticaria, Evommune's story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in eczema severity.

June 30, 2026

Tristan Manalac

BIOSPACE · NOV 5, 2026

Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca

---

AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.

Rhythm Pharmaceuticals' shares ended Wednesday up 24% on rumors that AstraZeneca had made a $10 billion bid to buy the biotech, which focuses on rare neuroendocrine diseases.

The Wall Street Journal reported the potential transaction, citing sources familiar with the matter. AstraZeneca reportedly offered $124 per share for Rhythm.

"We believe that this company would be a great strategic pickup for AstraZeneca," William Blair wrote Wednesday afternoon. The firm had selected Rhythm as a likely takeout target earlier this year, with multiple potential buyers given its metabolic focus.

"We believe any large-cap biopharma company with a metabolic (diabetes, obesity, etc.) could be interested in this company," the firm said. "In our view, that is basically every biopharma company out there."

The star of the buyout would be injectable weight loss drug Imcivree, which won approval in March for its third FDA indication, this time for acquired hypothalamic obesity (aHO). William Blair anticipated that the drug could hit $3.6 billion in sales by 2032, not including the potential for an approval in Prader-Willi syndrome. Rhythm is planning a Phase 3 trial for that rare disease later this year, according to the firm.

Mergers & acquisitions

Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One

Prime biotech buyout targets such as Revolution Medicines and Ascendis Pharma have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far.

March 19, 2026

Tristan Manalac

Earlier this week, Rhythm reported $92.1 million in global sales for Imcivree in the third quarter, an increase of 29% from the previous quarter. So far, the company has received over 700 patient start forms for the drug from more than 500 prescribers as of the end of September, according to the earnings report.

William Blair pointed to aHO—a condition involving accelerated and sustained weight gain caused by hypothalamic injury or dysfunction—as the most lucrative indication, with as many as 28,000 patients across the U.S., Europe and Japan, where the drug is being launched. Imcivree, first approved in 2020, is also cleared for chronic weight management for those with certain genetic mutations and Bardet-Biedl syndrome.

“What we have always liked so much about the aHO opportunity is that we see no competition in front of or behind it,” William Blair wrote. “GLPs do not work there, and setmelanotide [Imcivree] Phase 3 hit on its primary endpoint.”

The path for Imcivree has not been smooth sailing, however. A Phase 3 basket trial testing the drug in multiple genetic obesities failed earlier this year, just prior to the FDA’s aHO approval. The trial had featured patients with rare, genetically-driven obesities of the MC4R pathway. Analysts had expected at least one to hit, but all four genetic sub-studies were unsuccessful. Stifel had modeled $300 million in sales by 2034 for these genetic indications.

Rhythm has more coming up behind Imcivree, including the MC4R-specific agonist bivamelagon in aHO and RM-718 for aHO and Prader-Willi. The company also has a program in discovery for congenital hyperinsulinism.

A Phase 3 trial will be initiated for bivamelagon and enrollment for a Phase 1/2 trial of RM-718 should be completed by year-end, the company reported during earnings. Rhythm is also planning a study of bivamelagon in hyperphagia associated with Prader-Willi in 2027.

Rhythm had $320.9 million in cash on hand as of Sept. 30.

AstraZeneca reported earnings last week, with CEO Pascal Soriot saying that he is looking for potential business development options in oncology, cardiovascular, rare disease, immunology and respiratory disease. Leerink Partners recently flagged that the U.K. pharma has the potential for a transaction in the $10 billion range.

Mergers & acquisitions

Big Pharma is ready to strike, with J&J most likely to buy: Leerink

The largest pharmas have a collective $188 billion in firepower to spend on M&A transactions, with all but one signaling a desire to execute, according to a new analysis from Leerink Partners.

October 28, 2026

Annalee Armstrong

ISCB Career Compass: November 2026

In this issue:

Featured Jobs:

- Research Fellow - Biology
- Postdoc in Computational Genomics
- Faculty Member - Computational Biology, Machine Learning, & Digital Health
- Postdoctoral Associate
- Faculty Assistant Professor in Artificial Intelligence for Animal Improvement

Article: Reference Letters: Who to Ask, How to Ask, and How to Help

Closing Soon on the ISCB Career Center

Career Compass Featured Jobs

Research Fellow - BiologyThe Infinity FellowshipJob description:We are a frontier artificial-intelligence laboratory, still in stealth, established for a single purpose: to build an AI capable of original discovery — a system that does not merely retrieve and recombine what is already known, but reasons toward genuinely new understanding of the problems put to it. We hold that an instrument able to truly discover is among the most consequential technologies humanity will ever build, and we are building it.

Our system has already produced results beyond the reach of any human team. We have demonstrated its power on a small number of problems. The purpose of this fellowship is to establish how far that power extends.

This is an invitation to bring a small number of researchers who will form the inaugural cohort of the Infinity Fellowship who will spend a year aiming this instrument at the hardest unsolved problems in their fields.

You choose the problems — the ones shelved because they demanded a decade. You carry each from formulation to validated result. You publish as lead author.

The terms are plain: a full-time salaried appointment of roughly one year ($125,000), hybrid in the San Francisco East Bay, with relocation support and visa sponsorship for international Fellows. It pays like a strong postdoc. No background in AI is required; we weigh the ability to learn above experience with any method. Top-performing Fellows will be offered permanent research positions.

The application takes ten minutes to begin: your CV, and a few sentences on the problem you would start with. The full one-page proposal — why it has resisted solution, what its solution would make possible — can follow.

pfa.zto77.com/apply-biology-life-sciences

Proposals received by Sep 15 will be considered first for the inaugural cohort, which convenes in September. Every application receives an answer within a week.

Few are present, in any era, at the founding of a new instrument of discovery. Bring the problem worth your year.

Postdoc in Computational Genomics at Harvard School of Public HealthHarvard University Environmental Health, Biostatistics Cambridge, Massachusetts, USAJob description: The Broad Institute of MIT & Harvard is seeking a highly motivated computational Postdoctoral Associate to join the Haber Lab and Klarman Cell Observatory to discover the complex cellular processes and structures that underlie our airways ability to defend themselves from the wide range of threats in the air around us.

Our interdisciplinary research group uses machine learning and genomics to study the immunology of environmental health and particularly physiological mechanisms of lung inflammation and asthma. We use cutting edge genomics and computational methods to answer major questions in the field: how do the airways of the lungs detect danger signals, such as allergens, viruses, or toxins, and trigger an immune response? Which are the most important types of 'sentinel cells' that are on the lookout for danger in inhaled air, and able to co-ordinate an effective defense? Prospective applicants should have made significant contributions to their area of study, as evidenced by a strong publication record. We are seeking creative and highly motivated individuals who want to work in a dynamic, multi-disciplinary research environment.

Qualifications

- PhD or equivalent in computational biology, machine learning, data science, artificial intelligence, computer science, statistics, mathematics, or another quantitative field.
- Candidates holding a degree in biological or medical science are also welcome to apply if they have strong background in computational or statistical work.
- Strong interpersonal and communication skills, experience presenting and communicating research.
- Excellent problem solving and quantitative analysis skills

Faculty Member - Computational Biology, Machine Learning, & Digital HealthInstitute for Systems BiologySeattle, Washington, USAJob description: The Institute for Systems Biology (ISB) seeks a highly motivated and

talented Assistant, Associate, or Full Professor to join our faculty and lead transformative efforts in AI, machine learning, and computational biology to bridge the gap between basic science and next-generation medicine. The successful candidate will have a strong background in computational biology, statistics, machine learning/AI or a related field, and a passion for applying these techniques to address complex biological or medical problems.

Biomedical research pioneer Dr. Leroy Hood founded ISB in 2000 as the first-of-its-kind institute dedicated to systems biology. Unlike traditional academic departments, our faculty are cross-disciplinary, which enables us to take on big, complex problems. ISB is deeply committed to sharing our knowledge with society: we participate in the formation of companies, and strategically collaborate with healthcare systems and industry to improve human health and accelerate science.

ISB's computational capabilities are in biological modeling and simulation, machine learning, biostatistical methods, bioinformatics, medical informatics, applied to: genomics, phenomics and exposomics. ISB's technical capacities include genomics, transcriptomics, metagenomics, proteomics, metabolomics, imaging, and single-cell omics. Accordingly, ISB faculty develop novel measurement technologies, formal theories and computational tools to support all aspects of systems biology and systems medicine, and these unique resources are shared across the institute. ISB's affiliation with Providence, one of the largest not-for-profit health care systems in the United States, gives ISB access to unique resources including clinical trials, patient samples, 30 million electronic health records (EHRs), imaging, and the ability to translate discoveries into clinical applications that benefit patients.

Responsibilities:

- Establish and maintain a research program in applied mathematics, statistics, computer science or data science to investigate fundamental biological processes and their relevance to human health.
- Pioneer innovative computational frameworks to integrate multimodal biological and clinical data, such as genomics, proteomics, phenomics, or specialized domains, such as deep immunophenotyping, imaging, health dynamics, and spatiotemporalomics data that can drive new scientific paradigms or personalized medicine with actionable insights for patient care.
- Develop and apply innovative methods to integrate data-driven and knowledge-based approaches for discovery of mechanisms and clinical decision support.
- Collaborate with other researchers within the institute, external partners to translate computational discoveries into real-world applications in health care, from prevention to detection to treatment of diseases.
- Secure external funding to support research activities and expand the scope of the research program.
- Mentor graduate students, postdoctoral fellows, and undergraduate students.
- Contribute to ISB's research and educational mission.

Expected Salary: Compensation for this role will be based on skills, experience, and rank upon hire in the expected range of $155,000 to $300,000 per year.

Postdoctoral AssociateYale UniversityDepartment of BiostatisticsNew Haven, Connecticut, USAJob description: Leying Guan is an Associate Professor of Biostatistics at Yale Univ. Her team develops statistical and machine-learning methods for reliable scientific discovery from complex, high-dimensional data, along three interconnected directions: (1) models that capture structure in heterogeneous, high-dimensional data — latent-factor and multi-view models, structured/tensor estimation, high-dimensional regression, and integrative modeling; (2) inference that stays valid after complex or data-adaptive analysis — conformal prediction, robust inference, adaptive signal detection with error-rate control, and post-selection assessment; and (3) computational biology — building tools with improved statistical rigor for large-scale immune, single-cell, and multi-omics data, in collaboration with immunologists and consortium-scale data resources. Looking ahead, she is currently extending all three directions further toward new model structures and data types.

Depending on background and interest, projects may span new computational models for single-cell data targeting unresolved challenges; software and computational platform development with large-scale application to consortium data resources; theoretical and methodological development in robust uncertainty quantification or high-dimensional structured modeling. Candidates also have good flexibility to propose and develop their own research topics.

You don't need to fit all of these, but should be strong on at least one axis:

Methodologists: rigorous training in statistics, biostatistics, ML theory, comfortable enough with code and real data to implement and validate methods at scale.

Computational biologists / strong engineers moving into methodology: excellent software and data engineering skills (scalable computing, single-cell or genomic data pipelines).

ML-trained researchers curious about biology: strong deep learning background who are interested in working on problems with real statistical stakes in a biological domain and are motivated to learn the biology as they go.

Across all profiles, what matters most: genuine intellectual motivation, comfort working hands-on with real and large-scale data, and interest in building methods that are both theoretically sound and practically useful.

Compensation

Salary: Compensation will follow Yale University's postdoctoral compensation guidelines and will be commensurate with experience.

Preferred Start Date: Preferred Early 2027, but negotiable. Applications will be considered until the position is filled.

International applicants are welcome.

Qualifications

PhD (or near completion) in Statistics, Computer Science, Biostatistics, Computational Biology, or a related quantitative field, with a track record in either rigorous methodology, computational software development, or applying/extending computational methods to real, large-scale single cell/omics data.

Assistant Professor in Artificial Intelligence for Animal ImprovementPurdue University, Department of Animal SciencesIndianapolis, Indiana, USA Job description: Develop the next generation of data analytics and AI-enabled methods for selecting animals, deriving novel phenotypes, and implementing precision management or interventions to improve animal production systems.

Position

Purdue University invites applications for a tenure-track assistant professor position focused on data analytics and artificial intelligence (AI)-enabled selection in animal systems. This position will be housed in Indianapolis where the candidate will have the opportunity to shape the academic and research programs offered there. We seek an innovative scholar who develops and applies AI, machine learning, data science, genomics, biotechnology, and predictive modeling to improve decision-making across animal agriculture. The successful candidate will use advanced data science and AI-enabled techniques in areas of interest, including selection and breeding of animals, derivation of novel traits and high-throughput phenotypes, health interventions, infectious disease control, precision management strategies, or production systems. The ultimate goal is to help create the next generation of intelligent animal agriculture. Candidates developing foundational or applied methods in AI, computational biology, quantitative genetics, engineering, bioinformatics, multi-omics data analytics, statistics, or related fields whose work can accelerate improvement across livestock, poultry, aquaculture, companion animals, biomedical animal models, and other relevant animal systems are encouraged to apply. Prior research centered on agricultural animals is valued but not required when a candidate's expertise can be applied to consequential problems in animal agriculture and health.

The successful candidate will establish an internationally recognized and externally funded research program; collaborate across disciplines; mentor graduate students and postdoctoral scholars; and contribute to undergraduate and graduate education. The anticipated appointment will be in the Department of Animal Sciences with opportunities for collaboration and appropriate joint or courtesy appointments across Purdue.

Grand Challenge

How can advanced data analytics and AI enable faster, more accurate, and responsible genetic improvement and precision management to enhance animal health, resilience, productivity, welfare, and sustainability?

Potential Areas of Scholarship

- AI-enabled selection, breeding, and genetic improvement, including genomic prediction of breeding values and phenotypes and next-generation quantitative genetics
- Machine learning and foundation models that integrate genomic, phenotypic, environmental, management, imaging, sensor, and multi-omics data
- High-throughput and digital phenotyping using computer vision, acoustic monitoring, wearable and spectroscopic technologies, robotics, and advanced sensing/diagnostics
- Selection of animals and derivation of novel traits for animal health and welfare, disease resistance, climate resilience, reproduction, efficiency, and product quality
- AI-guided selection of nutritional, microbiome, therapeutic, or management interventions
- Digital twins, causal models, and decision systems that predict animal performance across environments and production systems
- Responsible and transparent AI, including model validation, interpretability, uncertainty, fairness, data governance, and deployment in real-world animal systems
- Large-scale and complex data integration from diverse livestock data sources
- Precision animal agriculture, autonomous monitoring, and producer-facing decision support
- One Health applications connecting animal, human, food, and environmental health

---

Responsibilities

- Develop a high-impact, externally funded research program in AI-enabled selection for farm animal systems.
- Publish foundational and translational scholarship in impactful venues in the field and develop data resources, algorithms, software, intellectual property, computing infrastructure, or deployable technologies as appropriate.
- Build interdisciplinary collaborations across agriculture, engineering, computing, veterinary medicine, life sciences, statistics, health, and livestock industries.
- Teach courses aligned with the candidate's expertise and contribute to curricula in AI, data science, genomics, biotechnology, quantitative methods, or animal systems. Course modality is

in person. The potential may exist for teaching online/distance courses during the academic year.
- Mentor undergraduate students, graduate students, visiting scholars, and postdoctoral researchers.
- Contribute service and engagement consistent with Purdue's land-grant mission.

Search More Jobs

Reference Letters: Who to Ask, How to Ask, and How to Help

Reference letters are a standard part of applying for positions, programs, or funding. They're also one of the pieces of applications that many people leave until the last minute. Thinking about reference letters early, being prepared, and making the process as easy as possible for referees is more likely to result in a strong letter that meaningfully supports your application.

Who to Ask

Remember that a reference letter is only as strong as the person's ability to speak to your work, your character, and your potential. A glowing but generic letter from someone who barely knows you will rarely serve you as well as a specific, enthusiastic one from someone who has worked closely with you.

Aim for references who can speak directly to different facets of your work and experience, rather than people to whom you only have a fleeting connection and who would all say essentially the same thing. Think about who you've worked with or learned from. A supervisor or PI, a dissertation committee member, or a professor who knows your academic work can all be great options.

How to Ask

Even if you're absolutely certain that the answer will be yes, reference letter etiquette dictates that you always ask someone, officially, to act as a reference for you. And when you do ask, do it early. Faculty and supervisors are busy, and a reference request made the week it's due is not only unprofessional, but it puts them in a time crunch and rarely results in a strong letter, if one is able to be written at all.

When you reach out, be direct about what you're asking for, providing as much context and detail from the outset as you can. A message that says "I'm applying for a postdoctoral position in computational genomics and I'd love to include you as a reference because of the work we did together on X" is far more compelling than a vague "would you be willing to write me a reference letter?"

Finally, remember that just because you ask them to write a reference letter doesn't mean your potential referee will say yes. Make it clear that you understand they might not be able to help. Something simple like "please let me know if you don't feel you're in a position to write a strong letter" signals that you respect their time and their honesty.

Setting Them Up for Success

The easier you make the process for your referee, the stronger the letter is likely to be. Once someone agrees to write you a reference letter, at minimum, you should send:

- Your current CV
- A clear description of the position or program you're applying for
- Any specific qualities or experiences you'd like them to highlight
- The submission deadline

If you worked on a project together that's relevant to the application, a brief reminder of that work can be helpful too. Referees are often writing multiple letters for multiple people, and a quick note jogging their memory about a particular project or accomplishment gives them concrete material to draw from.

Finally, always follow up with a thank you once the letter has been submitted and again when you hear back about the outcome, whatever it may be. It's a small gesture that goes a long way.

Final Thoughts

A strong reference letter is built before you send the request. It's the product of relationships you've invested in, work you've shown up for, and the care you take in how you ask. Approach the process thoughtfully and your references will be able to advocate for you in the ways that matter most!

Closing Soon on the ISCB Career Center

These jobs will be leaving the Career Center this month:

- MLOps Engineer — Iowa State University
- Ph.D. in Computational Biology and AI — Human Technopole / Politecnico di Milano
- Assistant or Associate Professor, Basic Sciences Division — Fred Hutchinson Cancer Center
- Research Fellow: AI for Molecular Modelling — Brunel University of London
- Faculty Position in BioAI at Cold Spring Harbor Laboratory — Cold Spring Harbor Laboratory
- ELLIS Institute Finland hiring: postdocs and PhD students in AI and machine learning — ELLIS Institute Finland
- Postdoc position - Microbiome Signatures of Heavy Menstrual Bleeding — Centre for Plant Biotechnology and Genomics
- Assistant Professor in Systems Biology — University of California, Irvine
- Postdoc position - Metagenomic mining & Bioprospecting of novel enzymes — Centre for Plant Biotechnology and Genomics
- Computational Biology Research Software Engineer — University of Liverpool

---

Want Your Job Featured in the Next Career Compass?

You can get your job featured in the Career Compass newsletter by selecting this option when you post a new job!

To do so, follow these steps:

1. Sign in to the ISCB Career Center.

2. From your Profile page or My Job Posts page, click the blue “Post a Job” button.
3. On the next page, select option 2 that mentions the monthly marketing with Career Compass.
4. Complete the required payment for the Career Compass upgrade.
5. Fill out your job post details.
6. Click “Submit” to post your job on the ISCB Career Center.
7. Keep an eye out for the next Career Compass newsletter to see your job there, too!

ISCB · OCT 26, 2026

ISCB's October 2026 Newsletter

- Support Us
- Join ISCB
- Contact Us
- Member Directory
- FAQ

Announcements

- November 4, 2026: ISCB Career Compass: November 2026
- October 26, 2026: ISCB's October 2026 Newsletter
- October 27, 2026: ISMB ECCB Proposal and Proceedings submissions are open
- October 12, 2026: 1 week left to register for LATAM tutorials
- October 7, 2026: ISCB Career Compass: October 2026

October 26, 2026: ISCB's October 2026 Newsletter

ISCB · OCT 27, 2026

ISMB ECCB Proposal and Proceedings submissions are open

ISMB ECCB proposal and Proceedings submissions are now open!

Read on for submission details and deadlines!

Tutorial Proposals

➡️ Submission deadline: Thursday, December 17, 2026

The purpose of tutorials is to provide attendees with the opportunity to build knowledge, gain hands-on training, develop new skills, or learn about emerging areas of bioinformatics research. Tutorials may include any form of presentation (e.g., brief talks, panel discussions) but must include hands-on exercises.

Further details and the proposal submission link can be found on the Call for Tutorials page.

Proceedings Papers

➡️ Submission deadline: Thursday, January 14, 2027

Submitted papers must follow the OUP template for author submissions to Bioinformatics. No other formats will be accepted. Papers must be submitted as a PDF, and paper length must not exceed 9 pages. The page count is inclusive of all author information, a 250-word abstract, figures (with alt text), tables, and references.

Accepted papers will be published in an open-access, online-only Proceedings Supplement issue of Bioinformatics. Authors of accepted papers will also be provided with a 20-minute oral presentation at the conference.

Click here to access the submission link and to review full submission guidelines before submitting your paper!

Technology Track Proposals

➡️ Submission deadline: Thursday, April 29, 2027

The tech track offers organizations an opportunity to showcase software and hardware innovations relevant to the bioinformatics community. Presentations should highlight the practical applications and benefits of the technology being demonstrated.

Full details about tech track presentations and the submission form can be found here. This form requires organizations to share a brief, 50-word description of the talk, as well as a one-page presentation overview.

Please make sure to review the fees associated with a tech track presentation. Note that tech track fees do not include the cost of conference registration.

ISCB · OCT 12, 2026

1 week left to register for LATAM tutorials

Don't forget to register for a tutorial at ISCB LATAM!

If you haven't registered for a tutorial, there's only one week left to do so! The last day to register for any tutorial that isn't sold out is next Monday, October 19.

Why Register for a Tutorial?

Tutorials provide you with the opportunity to gain knowledge and hands-on training in established or emerging topics in computational biology and bioinformatics. These in-depth sessions will allow you to deepen your skills, gain practical experience, and learn from leaders in the field!

Tutorial Options

There are in-person, satellite*, and virtual tutorial options, so whether you're attending LATAM in Lima, or from farther afield, you'll have the chance to expand your knowledge and skills.

The full list of tutorials can be found here. Be sure to register soon; spots in most tutorials are limited!

(*these tutorials are held in-person, but off-site from the main conference. They are available to Professional and Post-Doc registrants)

How to add a tutorial to your registration if you've already registered:

1. Find the email with the subject line "ISCB-LATAM 2026 Registration Confirmation" sent from This email address is being protected from spambots. You need JavaScript enabled to view it..
2. Click the link in that email that says "Click here to review or update your registration."
3. On the confirmation page, click the "Modify Registration" button found at the right of the screen.
4. Navigate to the "Tutorials" page.
5. Add the tutorials you wish to attend.
6. Click the continue buttons to complete your updated registration, including paying your new outstanding balance.

Register for ISCB LATAM!

ISCB · OCT 7, 2026

ISCB Career Compass: October 2026

In this issue:

Featured Jobs:

- Research Fellow - Biology
- Postdoc in Computational Genomics
- Faculty Member - Computational Biology, Machine Learning, & Digital Health
- Postdoctoral Associate

Article: Navigating Academic Doubt During Your PhD

Closing Soon on the ISCB Career Center

Career Compass Featured Jobs

Research Fellow - BiologyThe Infinity FellowshipJob description:We are a frontier artificial-intelligence laboratory, still in stealth, established for a single purpose: to build an AI capable of original discovery — a system that does not merely retrieve and recombine what is already known, but reasons toward genuinely new understanding of the problems put to it. We hold that an instrument able to truly discover is among the most consequential technologies humanity will ever build, and we are building it.

Our system has already produced results beyond the reach of any human team. We have demonstrated its power on a small number of problems. The purpose of this fellowship is to establish how far that power extends.

This is an invitation to bring a small number of researchers who will form the inaugural cohort of the Infinity Fellowship who will spend a year aiming this instrument at the hardest unsolved problems in their fields.

You choose the problems — the ones shelved because they demanded a decade. You carry each from formulation to validated result. You publish as lead author.

The terms are plain: a full-time salaried appointment of roughly one year ($125,000), hybrid in the San Francisco East Bay, with relocation support and visa sponsorship for international Fellows. It pays like a strong postdoc. No background in AI is required; we weigh the ability to learn above experience with any method. Top-performing Fellows will be offered permanent research positions.

The application takes ten minutes to begin: your CV, and a few sentences on the problem you would start with. The full one-page proposal — why it has resisted solution, what its solution would make possible — can follow.

pfa.zto77.com/apply-biology-life-sciences

Proposals received by Sep 15 will be considered first for the inaugural cohort, which convenes in September. Every application receives an answer within a week.

Few are present, in any era, at the founding of a new instrument of discovery. Bring the problem worth your year.

Postdoc in Computational Genomics at Harvard School of Public HealthHarvard University Environmental Health, Biostatistics Cambridge, Massachusetts, USAJob description: The Broad Institute of MIT & Harvard is seeking a highly motivated computational Postdoctoral Associate to join the Haber Lab and Klarman Cell Observatory to discover the complex cellular processes and structures that underlie our airways ability to defend themselves from the wide range of threats in the air around us.

Our interdisciplinary research group uses machine learning and genomics to study the immunology of environmental health and particularly physiological mechanisms of lung inflammation and asthma. We use cutting edge genomics and computational methods to answer major questions in the field: how do the airways of the lungs detect danger signals, such as allergens, viruses, or toxins, and trigger an immune response? Which are the most important types of ‘sentinel cells’ that are on the lookout for danger in inhaled air, and able to co-ordinate an

effective defense? Prospective applicants should have made significant contributions to their area of study, as evidenced by a strong publication record. We are seeking creative and highly motivated individuals who want to work in a dynamic, multi-disciplinary research environment.

Qualifications

- PhD or equivalent in computational biology, machine learning, data science, artificial intelligence, computer science, statistics, mathematics, or another quantitative field.
- Candidates holding a degree in biological or medical science are also welcome to apply if they have strong background in computational or statistical work.
- Strong interpersonal and communication skills, experience presenting and communicating research.
- Excellent problem solving and quantitative analysis skills

Faculty Member- Computational Biology, Machine Learning, & Digital HealthInstitute for Systems BiologySeattle, Washington, USAJob description: The Institute for Systems Biology (ISB) seeks a highly motivated and

talented Assistant, Associate, or Full Professor to join our faculty and lead transformative efforts in AI, machine learning, and computational biology to bridge the gap between basic science and next-generation medicine. The successful candidate will have a strong background in computational biology, statistics, machine learning/AI or a related field, and a passion for applying these techniques to address complex biological or medical problems.

Biomedical research pioneer Dr. Leroy Hood founded ISB in 2000 as the first-of-its-kind institute dedicated to systems biology. Unlike traditional academic departments, our faculty are cross-disciplinary, which enables us to take on big, complex problems. ISB is deeply committed to sharing our knowledge with society: we participate in the formation of companies, and strategically collaborate with healthcare systems and industry to improve human health and accelerate science.

ISB’s computational capabilities are in biological modeling and simulation, machine learning, biostatistical methods, bioinformatics, medical informatics, applied to: genomics, phenomics and exposomics. ISB's technical capacities include genomics, transcriptomics, metagenomics, proteomics, metabolomics, imaging, and single-cell omics. Accordingly, ISB faculty develop novel measurement technologies, formal theories and computational tools to support all aspects of systems biology and systems medicine, and these unique resources are shared across the institute. ISB’s affiliation with Providence, one of the largest not-for-profit health care systems in the United States, gives ISB access to unique resources including clinical trials, patient samples, 30 million electronic health records (EHRs), imaging, and the ability to translate discoveries into clinical applications that benefit patients.

Responsibilities:

- Establish and maintain a research program in applied mathematics, statistics, computer science or data science to investigate fundamental biological processes and their relevance to human health.
- Pioneer innovative computational frameworks to integrate multimodal biological and clinical data, such as genomics, proteomics, phenomics, or specialized domains, such as deep immunophenotyping, imaging, health dynamics, and spatiotemporalomics data that can drive new scientific paradigms or personalized medicine with actionable insights for patient care.

- Develop and apply innovative methods to integrate data-driven and knowledge-based approaches for discovery of mechanisms and clinical decision support.
- Collaborate with other researchers within the institute, external partners to translate computational discoveries into real-world applications in health care, from prevention to detection to treatment of diseases.
- Secure external funding to support research activities and expand the scope of the research program.
- Mentor graduate students, postdoctoral fellows, and undergraduate students.
- Contribute to ISB's research and educational mission.

Expected Salary: Compensation for this role will be based on skills, experience, and rank upon hire in the expected range of $155,000 to $300,000 per year.

Postdoctoral AssociateYale UniversityDepartment of BiostatisticsNew Haven, Connecticut, USAJob description: Leying Guan is an Associate Professor of Biostatistics at Yale Univ. Her team develops statistical and machine-learning methods for reliable scientific discovery from complex, high-dimensional data, along three interconnected directions: (1) models that capture structure in heterogeneous, high-dimensional data — latent-factor and multi-view models, structured/tensor estimation, high-dimensional regression, and integrative modeling; (2) inference that stays valid after complex or data-adaptive analysis — conformal prediction, robust inference, adaptive signal detection with error-rate control, and post-selection assessment; and (3) computational biology — building tools with improved statistical rigor for large-scale immune, single-cell, and multi-omics data, in collaboration with immunologists and consortium-scale data resources. Looking ahead, she is currently extending all three directions further toward new model structures and data types.

Depending on background and interest, projects may span new computational models for single-cell data targeting unresolved challenges; software and computational platform development with large-scale application to consortium data resources; theoretical and methodological development in robust uncertainty quantification or high-dimensional structured modeling. Candidates also have good flexibility to propose and develop their own research topics.

You don't need to fit all of these, but should be strong on at least one axis:

Methodologists: rigorous training in statistics, biostatistics, ML theory, comfortable enough with code and real data to implement and validate methods at scale.

Computational biologists / strong engineers moving into methodology: excellent software and data engineering skills (scalable computing, single-cell or genomic data pipelines).

ML-trained researchers curious about biology: strong deep learning background who are interested in working on problems with real statistical stakes in a biological domain and are motivated to learn the biology as they go.

Across all profiles, what matters most: genuine intellectual motivation, comfort working hands-on with real and large-scale data, and interest in building methods that are both theoretically sound and practically useful.

Compensation

Salary: Compensation will follow Yale University's postdoctoral compensation guidelines and will be commensurate with experience.

Preferred Start Date: Preferred Early 2027, but negotiable. Applications will be considered until the position is filled.

International applicants are welcome.

Qualifications

PhD (or near completion) in Statistics, Computer Science, Biostatistics, Computational Biology, or a related quantitative field, with a track record in either rigorous methodology, computational software development, or applying/extending computational methods to real, large-scale single cell/omics data.

Search More Jobs

Navigating Academic Doubt During Your PhD

For many PhD students, the end of the year is a natural time to pause and take stock of where things are headed. If questions about whether academia is still the right path have been creeping in, here are some things worth considering before making any major decisions.

How to Know When It's Time to Leave

The reality is that most people deciding whether to leave academia are weighing two very different kinds of evidence: the practical and the emotional. Knowing how to read both, and weigh them appropriately, is what makes the difference between a decision you feel good about and one you're second-guessing a year later.

The practical signals tend to show up in the day-to-day reality of your program. Research that has stalled despite your best efforts, a supervisory relationship that has become a consistent source of friction rather than support, or a quiet but growing sense that the degree itself is no longer something you actually want are all worth paying attention to rather than explaining away.

Emotional signals are just as real as the practical ones, but they require a little more interpretation. Frustration, exhaustion, and feeling undervalued are experiences most graduate students move through at some point, and on their own they don't mean much. What's worth paying attention to is persistence. When those feelings stop being tied to a specific setback, deadline, or difficult period and start feeling like the default state of being in your program, that's a signal of a different kind.

The Second Year Slump

Many PhD students find themselves hitting a wall around the two-year mark of their degree. At this point, the initial excitement of starting a new chapter has worn off, the work has probably gotten harder, a bit dull, or even more isolating, and the end still feels impossibly far away. This is a genuinely difficult phase, so it shouldn't come as a surprise that it's around this time that students start wondering if they've made a mistake.

Before making any major decisions during this period, it's worth considering whether what you're experiencing is actually burnout rather than a fundamental mismatch with academia. Burnout is common in graduate school and when it happens, it can make even the right path that you were excited about a couple years ago feel like the wrong one. If you find yourself answering "yes" to most of these questions, burnout may be worth addressing before making any permanent decisions:

- Did these feelings develop gradually after a particularly demanding period rather than being present from the start?
- Are there specific aspects of your program or environment driving how you feel, rather than a general sense that academia itself isn't right for you?
- Can you imagine feeling differently with a break, a change of supervisor, or a shift in your research direction?

If what you're experiencing isn't burnout but something more fundamental, that's worth taking seriously too. Talking to a mentor, counselor, or peers who've been through it can help you make sense of what you're feeling and what your options actually are.

Making a Decision Despite Uncertainty

Uncertainty doesn't go away just because you've thought about something long enough, and waiting for complete clarity before making your decision can become its own kind of stalling.

What can help is separating the decision from the fear. Leaving academia doesn't mean your PhD was a failure, and staying doesn't mean you're settling. Both paths have merit, and the right one is the one that aligns with what you actually want, not what you think you're supposed to want, or what the people around you expect.

If you're genuinely stuck, talking to people who have made both choices can be invaluable. Seek out researchers who left academia and built careers elsewhere, as well as those who stayed and found their footing. Their experiences won't make the decision for you, but they can make the options feel more concrete and less abstract.

Ultimately, no decision made thoughtfully and honestly is the wrong one. The goal isn't certainty, it's clarity on what matters most to you.

Final Thoughts

Deciding whether to stay in academia is rarely straightforward, and there's no formula that makes it easy. What matters most is that the decision is yours, and that it’s made thoughtfully, honestly, and on your own terms.

Closing Soon on the ISCB Career Center

These jobs will be leaving the Career Center this month:

- Computer Science Research Assistant Professor — Oklahoma Center of ImmunoEngineering
- ORISE-Fellow at NIH — NIH ODSS
- Staff Scientist [Bioinformatics/Metagenomics] — Małopolska Centre of Biotechnology, Jagiellonian University

- Associate or Full Professor — University of California San Diego
- Postdoctoral position in human disease genomics and computational biology — Icahn School of Medicine at Mount Sinai
- Computational biologist – single cell and spatial omics — University of Aberdeen
- NIH-funded postdoctoral position in Bioinformatics and Computational Systems Biology — National Institutes of Health (NIH), including National Institutes of Environmental Health Sciences (NIEHS) and National Cancer Institute (NCI)
- AI/ML for Biology - Four Tenure-Track Assistant Professor Positions — Duke University
- Opportunities at St. Jude Children's Research Hospital, Memphis, Tennessee
- Associate Biostatistician
- Bioinformatics Research Scientist
- Computational Postdoctoral Researcher – Bacterial Genomics, Transcriptomics, and Single-Cell Genomics
- Faculty Position - Department of Computational Biology (1)
- Faculty Position - Department of Computational Biology (2)
- Faculty Position - Department of Pathology, Computational Pathologist (1)
- Faculty Position - Department of Pathology, Computational Pathologist (2)
- Lead Biostatistician
- Postdoctoral Research Associate (dry lab) – Paul Geeleher
- Postdoctoral Research Associate (Mixed Computational Experimentalist)
- Scientist Scientific Software Engineer for Cryo ET Workflow Development
- Senior Bioinformatics Analyst
- Senior Computational Research Scientist (1)
- Senior Computational Research Scientist (2)
- Senior Image Data Scientist-Center for Bioimage Informatics
- Senior Staff Image Data Scientist — Time-Series & Neuroscience
- Senior Staff / Principal Software Engineer, Rust Genomics Infrastructure (1)
- Senior Staff / Principal Software Engineer, Rust Genomics Infrastructure (2)
- Staff Software Engineer / Machine Learning Engineer - Radiology

---

Want Your Job Featured in the Next Career Compass?

You can get your job featured in the Career Compass newsletter by selecting this option when you post a new job!

To do so, follow these steps:

1. Sign in to the ISCB Career Center.
2. From your Profile page or My Job Posts page, click the blue “Post a Job” button.

3. On the next page, select option 2 that mentions the monthly marketing with Career Compass.
4. Complete the required payment for the Career Compass upgrade.
5. Fill out your job post details.
6. Click “Submit” to post your job on the ISCB Career Center.
7. Keep an eye out for the next Career Compass newsletter to see your job there, too!

BIOINFORMATICS.ORG

Misc.: Obituary of Barry Bloom and the convergence of immunology, infectious disease, and public health

The full article could not be read from the source. Open the original

---

BIOINFORMATICS.ORG

Education: Creative Biolabs Scholarship Application Guide: Eligibility, Requirements, FAQs, and Tips for STEM Students

https://www.creative-biolabs.com/scholarship-program.html

Who Is Eligible for the Creative Biolabs Scholarship?

What Application Materials Are Required?

How to Apply, Step by Step

What Does the Selection Committee Look For?

Tips for Writing a Strong Essay or Presentation

Why This Scholarship Matters for Students in Biomedical and Life Science Fields

Final Checklist Before Submission

FAQs About the Creative Biolabs Scholarship

BIOINFORMATICS.ORG

Events: Free Webinar: DNA-Encoded Chemistry

The full article could not be read from the source. Open the original

---

BIOINFORMATICS.ORG

Events: BBCC2026 Bioinformatics and Computational Biology Conference

https://www.bbcc-meetings.it/bbcc2026/

- The deadline for submitting abstracts for oral presentations has been extended to 31 August due to technical issues encountered when abstracts containing special characters are submitted.
- Authors of abstracts already submitted will be notified of the acceptance of their abstracts by the specified date (8 September). For abstracts submitted in the last week of August, it may take a few more days to complete the assessment.
- All authors are asked to contact the organisers if they have not received any notification by 8 September.
- Abstracts for posters/short oral presentations may be submitted by 9 September at the latest. As the conference is fast approaching, there will be no further extensions to the deadlines.

https://www.bbcc-meetings.it/bbcc2026/

BIOINFORMATICS.ORG

Education: Webinar on Live Imaging of the Extracellular Matrix With a Glycan-Binding Fluorophore

- A cell-impermeable small molecule fluorophore turns on and red-shifts upon binding glycosylated biomolecules.
- Application of the dye to live biological samples enables wash-free visualization of the extracellular matrix structure.
- Observations demonstrate no toxicity, a broad substrate profile, deep tissue penetration, and negligible photobleaching in a variety of model organisms.

https://www.bocsci.com/webinar-live-imaging-of-the-extracellular-matrix-with-a-glycan-binding-fluorophore.html

https://pedramlab.com

MOST VIEWED ON BIOINFORMATICS.NET

OCT 28, 2025 · 6 VIEWS

Bioinformatics.net Announces Annual Conference in San Diego, CA

The 2026 Bioinformatics.net Annual Conference will convene researchers, clinicians, and industry partners in San Diego for three days of talks on single-cell analysis, AI-assisted genomics, and community infrastructure. The program is designed for both wet-lab scientists who need clearer computational partnerships and software engineers who want deeper biological context.

Sessions will span invited keynotes, parallel scientific tracks, and hands-on workshops covering quality control, annotation, cloud workflows, and reproducible reporting. Morning plenaries set shared themes for the day, while afternoon breakouts let attendees dig into methods that match their lab's maturity and tooling stack. Evening networking is structured around affinity tables so newcomers can meet peers working on similar problems.

Abstract submissions are now open to members, with early registration discounts available through the end of the year. Authors may propose short talks, posters, or tool demos; reviewers will prioritize clarity, open artifacts, and practical reuse. Accepted presenters receive guidance on slide templates, dataset licensing notes, and how to link supporting materials from the conference site.

Attendees can expect curated networking, exhibitor demos, and a closing panel on open science practice. Hotel blocks near the venue will be announced with registration, and travel support applications for students and early-career members open next month. Full agenda updates will appear here as tracks are finalized.

SEP 30, 2025 · 3 VIEWS

New Resources Added to the Bioinformatics Toolkit

Editors expanded the resource catalogs with curated glossaries, data viewers, and language reference cards so members can search, filter, and browse production-ready tables across the site.

Each entry includes a short description, tags, and links suited to daily bioinformatics work. Admin CSV import and per-entry editing remain available for maintainers who need to append or correct records. Feedback from early reviewers already shaped table density, search filters, and mobile reading width, including clearer empty states when a filter returns no rows.

Additional curated directories for software, teaching materials, and data portals continue to grow as editors incorporate community recommendations. If you spot a missing field or an awkward label while browsing, submit a short note through the product request form so the schema and copy can be refined.

OCT 20, 2025 · 1 VIEW

New Study Highlights AI Advances in Genomic Analysis

A community working group reviewed recent machine-learning methods for variant interpretation and highlighted open datasets that members can reuse in their own pipelines. The goal was not to crown a single winner, but to map where models help, where they struggle, and what labs should verify before adopting a method in production.

The summary walks through benchmark choices, common failure modes on rare variants, and practical notes on when classical statistical approaches still outperform deep models. Contributors compared calibration, compute cost, and how well methods transfer across ancestries and assay platforms. Several case studies show how small label errors or batch effects can inflate apparent accuracy if evaluation sets are not held out carefully.

Companion notebooks and dataset links will be posted in the Resources section for members who want to reproduce the examples. Each notebook includes environment files, a short README, and suggested negative controls so teams can stress-test claims against their own cohorts. Feedback from the first review round already improved the reporting checklist for future methods notes.

The working group will host a follow-up office hour for members who want help adapting the evaluation protocol. Questions about licensing, clinical caveats, or contribution guidelines can be sent through the contact form with the subject line “AI genomics review.”

OCT 15, 2025 · 0 VIEWS

Call for Abstracts — 2026 Annual Meeting

Poster and talk abstracts are invited through January for the 2026 annual meeting. We welcome submissions from academic labs, clinical groups, biotech teams, and independent practitioners who want to share methods that others can actually run.

Preference is given to reproducible workflows, shared data resources, and teaching materials that other labs can adopt without proprietary lock-in. Submissions may cover methods, tooling, clinical applications, or community infrastructure, and authors can indicate whether they prefer a short talk or poster. Abstracts should state the problem, approach, evidence of reuse, and any limitations reviewers should weigh.

Reviewers will prioritize clarity, open artifacts, and relevance to practicing bioinformaticians. Supplementary links to repositories, protocols, or reference cards are encouraged and will be linked from the program once talks are accepted. Notification of acceptance is expected in early spring, with camera-ready updates due several weeks before the meeting.

Members who are unsure whether a project fits can browse last year’s themes or ask an editor for a quick fit check. Travel awards and childcare stipends will be announced alongside acceptance letters so presenters can plan early.

OCT 8, 2025 · 0 VIEWS

Member Spotlight: Dr. Priya Natarajan

Dr. Priya Natarajan, a computational biologist at Genentech, talks about how community directories and events helped her find collaborators and stay current with methods outside her immediate team. Her work sits at the intersection of production genomics pipelines and exploratory method development, which means she constantly evaluates whether a new tool is ready for wider adoption.

In this spotlight she shares how she evaluates new tools, mentors junior analysts, and balances delivery timelines with the curiosity that keeps a group innovative. She describes a lightweight review checklist her team uses for packaging, documentation, and failure modes before promoting a method from a notebook into a shared service. She also reflects on the value of shared glossaries and job boards when hiring across specialties that do not share the same vocabulary.

Priya credits early conference hallway conversations and directory lookups for introductions that later became co-authored work. She encourages members to publish short notes, not only polished papers, so others can learn from partial progress. The full interview covers her path into industry, advice for members building a first public portfolio, and how she protects focus time while staying visible in the community.

A condensed version of her reading list and hiring prompts will be added to the Resources section next week for members who want to reuse the same framing with their own teams.

TOP JOB POSTS

Fewer than 10 jobs were published last month. This list includes the most recent published jobs.

Senior Staff / Principal Software Engineer, Rust Genomics Infrastructure

St Jude Children's Research Hospital · Full time

Postdoc Fellow

University of Virginia · Full time

Post-doc in Protein Docking, Virtual Screening, and Genomics

University of Nebraska Medical Center · Full time

Postdoctoral Research Fellow - Computational Biologist - Gillani Lab

Dana-Farber Cancer Institute · Full time

Assistant Professor Faculty Positions, Genetics and Genomic Sciences

Icahn School of Medicine at Mount Sinai - Genetics and Genomic Sciences · Full time

Data Scientist - Clinical Machine Learning & Flow Cytometry

St Jude Children's Research Hospital · Full time

Associate Scientist - Single Cell Genomics Core / Neurocytometry Core

St Jude Children's Research Hospital · Full time

Charles H. Babcock Chair of Botany in Plant Genomics

Wake Forest University - Department of Biology · Full time

Computational Biologist / Postdoctoral Fellow - Epigenomics, Machine Learning & 3D Genome Biology

NYU Langone Health, Skok Lab · Full time

Bioinformatics Software Engineer -- build cloud MRD pipelines

Allovista · Full time

LATEST PUBLICATIONS

circCRIM1 inhibits endothelial cell ferroptosis in atherosclerosis via regulating miR-567/PRDX3 pathway.

Cytotechnology · 2026-11-02

Integrated multi-omics analysis reveals distinct metabolic signatures and gut microbiome alterations across the pediatric obesity spectrum.

Gut Microbes · 2026-11-01

A microbiota-metabolite-glial axis drives white matter repair via isorhamnetin-PSAP-GPR37 signaling after ischemic stroke.

Gut Microbes · 2026-11-01

A Multidimensional Framework for Integrated Toxicity Assessment and Prioritization of Naphthenic Acids in Marine Medaka (Oryzias melastigma): Neurotoxicity and Mechanistic Insights.

Environ Sci Technol · 2026-11-01

Advances in HIV-associated pulmonary diseases: an official American Thoracic Society workshop report.

Ann Am Thorac Soc · 2026-11-03

Harnessing yeast biodiversity to identify superior chassis strains for metabolic engineering and precision fermentation.

FEMS Yeast Res · 2026-11-03

Identification of Potential Biomarkers for Ulcerative Colitis and Analysis of Immune Cell Infiltration: A Study Based on Data-Independent Acquisition Proteomics and the GEO Public Database.

Proteomics Clin Appl · 2026-11-01

Phosphoprotein Phosphatases (PPP), Important Molecular Switchers in Plant Cell and Environment Responses.

Plant Cell Environ · 2026-11-03

GRANTS

Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)

Closes 03/05/2029

NICHD Resource Program Grants in Bioinformatics (P41 Clinical Trial Not Allowed)

Closes 09/25/2027

HEAL Initiative: Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins and the Nature of (PRECISION) Human Pain Network

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genomic Research Centers

Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)

Infrastructure Innovation for Biological Research (Innovation)
Closes 10/30/2076

Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Closes 05/07/2028

Immune Tolerance Network (UM1 Clinical Trial Required)
Closes 01/29/2027

Centers for Genomics Research Capacity Building

HEAL Initiative: Optimization of Therapeutic Medical Devices through Team Science Mechanistic Research (RM1)

NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research
Closes 12/30/2026

ancient DNA for Modern Genomics (aDMG) Data Generation and Resource Center